 
Celsion Corporation   XXXXXXXXXX   
CLINICAL PROTOCOL 1 
 
 
Study Title:  A Phase III, Randomized, Double Blind, Dummy -Controlled Study 
of ThermoDox® (Lyso -Thermosensitive Liposomal Doxorubicin -
LTLD) in Hepatocellular Ca rcinoma  (HCC) using standardized  
Radiofrequency Ablation  (RFA)  treatment time ≥ 45 minutes for 
solitary lesions ≥ 3 cm to ≤ 7 cm.  
 
Protocol Number:  104-13-302 
 
Protocol Version /Date:  Version 2.0, 1 4-March -2014    
 
Prior Versions /Date :  Version 1.0, 13 -January -2014  
 
Investigational Product:  ThermoDox® (Lyso -Thermosensitive  Liposomal Doxorubicin) 
 
Development Phase:  3 
 
Sponsor:  Celsion Corporation  
997 Lenox Drive, Suite 100  
Lawrenceville, NJ  08648   USA  
 
IND Number:  66,827  
 
EudraCT Number:   2014 -000934 -53   
 
NCT Number:  02112656  
 
 
 
 
 
 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXX . 

Protocol No.: 104 -13-302   Page 2 of 103 
Version 2.0, 14 -March -2014  
Celsion Corporation   XXXXXXXXXX  LIST OF STUDY REPRESENTATIVES  
The list of organizations below have  responsibilities for oversight and conduct of the clinical study  
that will be identified  in a transfer of responsibility document . Contact details are consistent at the 
time of the final protocol.  
 
Sponsor  Celsion Corporation  
997 Lenox Drive Suite 100  
Lawrenceville, NJ 08648  
Phone: XXXXXXXXXX             Fax: (XXXXXXXXXX 0 
Sponsor Medical Expert  XXXXXXXXXX   
Celsion Corporation  
Senior Vice President and Chief Medical Officer  
Phone: XXXXXXXXXX  
Medical Monitor 
Representatives  Asia Pacific  
Accelovance  
XXXXXXXXXX . 
XXXXXXXXXX  
Phone: XXXXXXXXXX   Europe/North America  
Drug Safety Solutions  
XXXXXXXXXX . 
XXXXXXXXXX   
Phone:  XXXXXXXXXX  
SAE Reporting  InVentiv Pharmacovigilance - Fax Reporting  
North America  Mainland China  Europe and ROW  
XXXXXXXXXX  XXXXXXXXXX  XXXXXXXXXX  
Organization 
Responsible for 
Monitoring Trial  InVentiv Health  Clinical  
504 Carnegie Center  
Princeton, NJ 08540         
USA   
Telephone: XXXXXXXXXX                Fax: XXXXXXXXXX  
EU Legal 
Representation  PharmaNet Ltd  
Thames House  
17-19 Marlow Road  
Berkshire SL6 7AA  
United Kingdom  
 
Protocol No.: 104 -13-302   Page 3 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Investigational Product 
Supplier  Sharp Clinical Supply  Packaging        Sharp Clinical Distribution  
300 Kimberton Road                           1041 W. Bridge Street  
Phoenixville, PA 19460                       Phoenixville, PA 19460  
USA  USA  
Telephone: XXXXXXXXXX  
Administrative changes during the study may not require amendment to the protocol. Future  changes 
will be recorded in the transfer of responsibility document . 
 
Coordinating Investigators  
 
Mainland China  Chen Min Hua, M.D.  
Beijing University Cancer Hospital  
No. 52 Fu Cheng Road  
Haidian District  
Beijing , 100142, People’s Republic of China  
Asia/ Pacific  Ronnie T. Poon, M.D.  
The University of Hong Kong, Dept. of Surgery 3/F Block L  
Queen Mary Hospital  
102 Pokfulam Road  
Hong Kong, People’ s Republic of China  
Europe  
 Riccardo Lencioni, M.D.  
Ospedale Cisanello, University of Pisa  
Via Paradisa, 2  
Pisa 56124, Italy  
Responsible 
Investigators and 
Laboratories  FDA Form 1572 will capture list of Responsible Investigator’s 
and Laboratories utilized for the trial.  
Protocol No.: 104 -13-302   Page 4 of 103 
Version 2.0, 14 -March -2014  
Celsion Corporation   XXXXXXXXXX   
RATIONAL FOR AMENDMENT CHANGES  
 
Protocol Version 1.0 13 -January -2014 to Version 2.0, 14 -March -2014  
 
Overview of Changes  
The protocol a mendment i s issued to address regulatory comments received on 4 -Mar-2014 
from U.S. FDA.  The overview of the changes include  
1. Minor edits to the inclusion criteria to further characterize the RFA procedure 
duration ≥ 4 5 minutes and to the exclusion criteria increasing baseline platelet level 
counts to 75,000/mm3 
2. Standardize follow up visit s to evaluate safety and PFS at consistent interval s. 
3. Provide further guidance  for consistency in reporting i nvestigator determined PFS 
definitions  in Section 12.0.  
4. Administrative  change s made throughout the protocol may not be detailed in 20.10  of 
changes  
A table listing the changes in each protocol section is detailed in Appendix X  of the protocol .  
 
  
Protocol No.: 104 -13-302   Page 5 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
STATEMENT OF COMPLIANCE  
 
The procedures set out in this study protocol are designed to ensure that Celsion and 
Investigator abide by the principles of the Guideline for Good Clinical Practice (GCP) of the 
International Conference on Harmonisation (ICH) and the Declaration of Helsinki in the 
conduct, evaluation and documentation of this study, required by the following:  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical 
studies (45 CFR Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312).  
• EU Directive 2001/20EC of April 2001, in those countries where the directive is 
fully implemented  
 
Before the start of the study, the study protocol, written informed consent form(s) and/or 
other appropriate documents will be submitted to the Independent Ethics Committee and/or 
the authorities, in accordance with local legal requirements.  
 
In addition, any advertising materials must be approved by Celsion Clinical Affairs  and an 
Independent Ethics Committee  before use. The study will be conducted in accordance with 
US FDA, applicable national and local health authorities and the IEC requirements.  
 
All study personnel are required to have proper training  on study procedures and GCP 
guidelines on protection of subject interests, health and confidentiality.  
 
 
 
 
 
 
 
 
 
 
Protocol No.: 104 -13-302   Page 6 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  SIGNATURE PAGE FOR SPONSOR  
 
IND No. 66,827  
Study No. 104-13-302 
Title: A Phase III, Randomized, Double Blind, Dummy -Controlled Study of 
ThermoDox® (Lyso -Thermosensitive Liposomal Doxorubicin -LTLD) in Hepatocellular 
Carcinoma (HCC) using standardized Radiofrequency Ablation (RFA) treatment time 
≥ 45 minutes for solitary lesions ≥ 3 cm to ≤ 7 cm.  
 
This study protocol was reviewed internally and with Medical consultants and has been 
approved by the appropriate study protocol review committee.  The information it contains is 
consistent with:  
 
1. Investigator's Brochure with details of pharmacological and toxicological findings 
with the Investigational Product, and  
 
2. The moral, ethical and scientific principles governing clinical research as set out 
in the Declaration of Helsinki and Good Clinical Practice guidelines.  
The Investigator will be supplied with details of any significant or new findings, including 
adverse events.   
 
Approved by the following:  
 
XXXXXXXXXX  
Senior Vice President and Chief Medical Officer  
Celsion Corporation  
997 Lenox Drive, Suite 100  
Lawrenceville, NJ   08648  USA  
 
 
 
 
 
 
 
  Signature    Date  
Protocol No.: 104 -13-302   Page 7 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  SIGNATURE PAGE FOR INVESTIGATOR  
 
IND No. 66,827  
Study No. 104-13-302 
Title: A Phase III, Randomized, Double Blind, Dummy -Controlled Study of ThermoDox® 
(Lyso -Thermosensitive Liposomal Doxorubicin -LTLD) in Hepatocellular Carcinoma  (HCC) 
using standardized Radiofrequency Ablation (RFA) treatment time ≥ 45 minutes for solitary 
lesions ≥ 3 cm to ≤ 7 cm.  
 
I have carefully read this protocol and agree that it contains all the necessary information 
required to conduct the study.  I agree to conduct this study as outlined in the protocol.  
1. I understand that this study will not be initiated without approval of the appropriate 
Institutional Review Board/Research Ethics Board/Independent Ethics Committee 
(IRB/REB/IEC), and that all administrative requirements of the governing body of the 
Institution will be complied with fully.  
2. Informed written consent will be obtained from all participating subjects in 
accordance with institutional guidelines, FDA requirements as specified in Title 21 
CFR, Part 50, the European Union Directive 2001/20/EC and its associated Detailed 
Guidances, the ICH Guideline for Good Clinical Practice, and the terms of the 
Declaration of Helsinki.  
3. I will enroll subjects who meet the protocol criteria for entry.  
4. I understand that I am responsible for medical supervision during the conduct of this 
protocol.  
5. I understand that my signature on each completed Case Report Form indicates that I 
have carefully reviewed each page and accept full responsibility for the contents 
thereof.  
6. I understand that the information presented in this study protocol is confidential, and I 
hereby assure that no information based on the conduct of the study will be released 
without prior consent from the Sponsor unless this requirement is superseded by the 
Food and Drug Administration, a Competent Authority of the European Union, China 
Food and Drug Administration or another Regulatory Authority.  
 
 
Investigator Name    Signature    Date  
 
Investigator Position   Investigator Address   
  
Protocol No.: 104 -13-302   Page 8 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   Table of Contents  
 
List of Study Representatives  ................................ ................................ ................................ .2 
RATIONAL FOR AMENDMENT CHANGES  ................................ ................................ ....4 
STATEMENT OF COMPLIANCE  ................................ ................................ ....................... 5 
SIGNATURE PAGE FOR SPONSOR  ................................ ................................ .................. 6 
SIGNATURE PAGE FOR INVESTIGATOR  ................................ ................................ ......7 
Table of Contents  ................................ ................................ ................................ ..................... 8 
1. PROTOCOL SYNOPSIS  ................................ ................................ ................................ ..12 
2. LIST OF ABBREVIATIONS  ................................ ................................ ........................... 19 
3. INTRODUCTION ................................ ................................ ................................ .............. 22 
3.1 OVERVIEW  ................................ ................................ ................................ ................ 22 
3.2 RADIOFREQUENCY ABLATION (RFA)  ................................ ................................ .......22 
3.3   THERMO DOX ................................ ................................ ................................ ............ 24 
4. OBJECTIVES  ................................ ................................ ................................ .................... 25 
4.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ 25 
4.1.1  Measurement of the Primary Objective  ................................ ..........................  25 
4.2 SECONDARY OBJECTIVES  ................................ ................................ .......................... 26 
4.2.1  Measurement of Secondary Objectives  ................................ ..........................  26 
5. STUDY PLAN  ................................ ................................ ................................ .................... 27 
5.1 DESIGN OVERVIEW  ................................ ................................ ................................ ...27 
5.2 TRIAL TERMINATION  ................................ ................................ ................................ 30 
6. STUDY POPULATION  ................................ ................................ ................................ ....30 
6.1 SOURCE AND NUMBER OF SUBJECTS  ................................ ................................ ......... 30 
6.2 SUBJECT SELECTION CRITERIA  ................................ ................................ ................. 30 
6.2.1  Overview  ................................ ................................ ................................ .........  30 
6.2.2  Inclusion Criteria  ................................ ................................ ............................  30 
6.2.3  Exclusion Criteria  ................................ ................................ ...........................  31 
6.2.4  Potential Risks and Benefits  ................................ ................................ ...........  32 
7. ENROLLMENT AND WITHDRAWAL PROCEDURES  ................................ ............ 35 
7.1 ENROLLMENT PROCEDURES  ................................ ................................ ...................... 35 
7.2 SUBJECT DISCONTINUATION  ................................ ................................ ..................... 35 
7.3 STUDY NONCOMPLIANCE  ................................ ................................ .......................... 36 
7.4 END OF THE STUDY  ................................ ................................ ................................ ...36 
8. STUDY TREATMENT ADMINISTRATION  ................................ ................................ 36 
8.1 ALLOCATION TO TREATMENT  ................................ ................................ ................... 36 
8.2 PRE-MEDICATION AND THERMO DOX ADMINISTRATION ................................ ........... 36 
8.3 USE OF RADIOFREQUENCY ABLATION DEVICES  ................................ ....................... 38 
8.4 RADIOFREQUENCY ABLATION PROCEDURE  ................................ .............................. 38 
8.5 DOSE MODIFICATIONS  ................................ ................................ .............................. 40 
Protocol No.: 104 -13-302   Page 9 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  8.5.1  Hepatobiliary Surveillance ................................ ................................ ..............  40 
8.5.2  Suggested Management for Hypersensitivity Reactions:  ...............................  40 
8.5.3  Extravasations  ................................ ................................ ................................ . 40 
8.5.4  Dose Modification for Re -Treatment ONLY  ................................ .................  40 
9. STUDY MEDICATION  ................................ ................................ ................................ ....41 
9.1 CLINICAL SUPPLIES  ................................ ................................ ................................ ...42 
9.2 PACKAGING AND LABELING  ................................ ................................ ...................... 42 
9.3 STORAGE OF STUDY MEDICATION  ................................ ................................ ............ 43 
9.4 THAWING , STABILITY , AND RECONSTITUTION OF THERMO DOX ............................... 43 
9.5 DRUG ACCOUNTABILITY /DISPOSITION OF CLINICAL TRIAL SUPPLIES  ...................... 43 
10. SCHEDULE OF STUDY PROCEDURES  ................................ ................................ .44 
10.1  STUDY PROCEDURES  ................................ ................................ ................................ .47 
10.1.1  Screening Overview  ................................ ................................ ........................  47 
10.1.2  Subject Numbering  ................................ ................................ .........................  47 
10.1.3  Demographics and Medical History  ................................ ...............................  47 
10.1.4  Disease History and Biopsy  ................................ ................................ ............  47 
10.1.5  Physical Exam  ................................ ................................ ................................ . 48 
10.1.6  Vital Signs  ................................ ................................ ................................ ....... 48 
10.1.7  ECOG Performance Status  ................................ ................................ .............  49 
10.1.8  Imaging  ................................ ................................ ................................ ...........  49 
10.1.9  ECG ................................ ................................ ................................ .................  49 
10.1.10  ECHO/MUGA Scan for LVEF Monitoring  ................................ ....................  50 
10.1.11  Serum Pregnancy Test  ................................ ................................ ....................  50 
10.1.12  Laboratory Analytes ................................ ................................ ........................  50 
10.2  RE-TREATMENT  ................................ ................................ ................................ ........ 51 
10.3  UNSCHEDULED ASSESSMENTS AND EARLY DISCONTINUATION  ................................ 51 
11. CONCOMITANT MEDICATIONS  ................................ ................................ ........... 52 
12. ASSESSMENT OF EFFICACY  ................................ ................................ .................. 53 
12.1  PRIMARY ENDPOINT : SURVIVAL  ................................ ................................ ............... 53 
12.2  SECONDARY ENDPOINT : PROGRESSION FREE SURVIVAL  ................................ .......... 53 
12.3  BASELINE ASSESSMENT  ................................ ................................ ............................ 53 
12.4  TARGET LESION RESPONSE AND LOCAL RECURRENCE  ................................ ............. 54 
12.4.1  Response Criteria for Assessing Index Lesion  ................................ ...............  54 
13. ASSESSMENT OF SAFETY  ................................ ................................ ....................... 57 
14. ADVERSE EVENTS  ................................ ................................ ................................ ....57 
14.1  LABORATORY TEST RESULTS  ................................ ................................ ................... 58 
14.2  OVERDOSE  ................................ ................................ ................................ ................ 59 
14.3  NON-SERIOUS CLINICAL ADVERSE EVENTS ................................ .............................. 59 
14.4  SERIOUS ADVERSE EVENTS (SAE)  ................................ ................................ ........... 59 
14.4.1  Definition of Life -Threatening Adverse Experiences  ................................ ..... 60 
14.4.2  Definition of Disabling/Incapacitating Experiences  ................................ ....... 60 
14.4.3  Reporting of SAEs  ................................ ................................ ..........................  60 
14.5  OTHER EVENTS  ................................ ................................ ................................ ......... 62 
Protocol No.: 104 -13-302   Page 10 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  15. STATISTICS  ................................ ................................ ................................ ................. 62 
15.1  STUDY POPULATIONS  ................................ ................................ ................................ 62 
15.2  STUDY ENDPOINTS  ................................ ................................ ................................ ....62 
15.2.1  Primary Endpoint – Overall Survival (OS)  ................................ .....................  62 
15.2.2  Secondary Endpoints  ................................ ................................ ......................  63 
15.2.2.1  Progression -Free Survival (PFS)  ................................ ............................  63 
15.3  STATISTICAL ANALYSIS  ................................ ................................ ............................ 63 
15.3.1  Subject Disposition, Baseline and Treatment Characteristics  ........................  63 
15.3.1.1  Subject Disposition  ................................ ................................ .................  63 
15.3.1.2  Subject Baseline Characteristics  ................................ .............................  63 
15.3.1.3  Study Treatment  ................................ ................................ ......................  63 
15.3.1.4  Non-Study Treatment in the Study Follow -up Period  ............................  63 
15.3.2  Efficacy Analyses  ................................ ................................ ...........................  63 
15.3.2.1  Primary Efficacy Analysis  ................................ ................................ ...... 63 
15.3.2.2  OS - Supportive Analyses  ................................ ................................ ....... 64 
15.3.2.3  Secondary Endpoint Analyses  ................................ ................................  64 
15.3.2.4  Safety Analyses  ................................ ................................ .......................  65 
15.4  DETERMINATION OF SAMPLE SIZE ................................ ................................ ............ 65 
15.4.1  Study Population  ................................ ................................ .............................  65 
15.5  INTERIM ANALYSES  ................................ ................................ ................................ ..65 
16. DATA HANDLING  ................................ ................................ ................................ ......66 
16.1  DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  ................................ ...................... 66 
16.2  QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ....................... 66 
16.2.1  Monitoring of the Study and Regulatory Compliance  ................................ .... 66 
16.2.2  Curricula Vitae and Financial Disclosure of Investigators  .............................  67 
16.2.3  Protocol Modifications ................................ ................................ ....................  67 
16.3  DATA HANDLING AND RECORD KEEPING  ................................ ................................ .67 
16.3.1  Data Collection  ................................ ................................ ...............................  68 
16.3.2  Recording of Data  ................................ ................................ ...........................  68 
16.3.3  Study Records  ................................ ................................ ................................ . 68 
16.4  FINANCING AND INSURANCE  ................................ ................................ ..................... 68 
16.5  PUBLICATION POLICY  ................................ ................................ ............................... 69 
17. ETHICAL CONSIDERATIONS  ................................ ................................ ................. 69 
17.1  INFORMED CONSENT  ................................ ................................ ................................ .70 
17.2  INSTITUTIONAL REVIEW BOARD /RESEARCH ETHICS BOARD /INDEPENDENT 
ETHICS COMMITTEE  ................................ ................................ ................................ ..70 
17.3  SUBJECT PROTECTION  ................................ ................................ ............................... 70 
17.3.1  Subject Privacy  ................................ ................................ ...............................  70 
17.3.2  Rationale for Subject Selection  ................................ ................................ ....... 71 
17.3.3  Participation of Children  ................................ ................................ .................  71 
18. TRIAL ADMINISTRATIVE INFORMATION  ................................ ........................ 71 
18.1  PROTOCOL AMENDMENTS  ................................ ................................ ......................... 71 
19. REFERENCES  ................................ ................................ ................................ .............. 72 
Protocol No.: 104 -13-302   Page 11 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  20. APPENDICES  ................................ ................................ ................................ ............... 75 
20.1  APPENDIX I: CHILD -PUGH CLASSIFICATION OF HEPATIC IMPAIRMENT  ..................... 75 
20.2  APPENDIX II: NEW YORK HEART ASSOCIATION (NYHA)  FUNCTIONAL 
CLASSIFICATION FOR HEART FAILURE  ................................ ................................ ......76 
20.3  APPENDIX III: PROHIBITED MEDICATIONS  ................................ ................................ 77 
20.4  APPENDIX IV: RFA  TREATMENT PROCEDURE  ................................ .......................... 79 
20.5  APPENDIX V: ADVERSE EVENTS (AE S) AND CRITERIA FOR DETERMINING 
RELATIONSHIP OF AE TO TREATMENT  ................................ ................................ ......80 
20.6  APPENDIX VI:  ECOG  PERFORMANCE STATUS  ................................ ......................... 82 
20.7  APPENDIX VII:  REQUIREMENTS OF WRITTEN INFORMED CONSENT DOCUMENT 
(21 CFR  50.20  AND 50.25  AND ICH  GCP,  TOPIC E6, SECTION 4.8) ......................... 83 
20.8  APPENDIX VIII:  AASLD  DIAGNOSTIC CRITERIA  ................................ ...................... 85 
20.9  APPENDIX IX: LINK TO THE MOST RECENT VERSION OF NCI  COMMON TOXICITY 
CRITERIA FOR ADVERSE EVENTS (CTCAE),  VERSION 4................................ ........... 87 
20.10  APPENDIX X: DESCRIPTION OF AMENDMENT CHANGES  ................................ ........... 88   
Protocol No.: 104 -13-302   Page 12 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  1. PROTOCOL  SYNOPSIS  
Title of Study  A Phase III, Randomized, Double Blind, Dummy -Controlled Study of ThermoDox® 
(Lyso -Thermosensitive Liposomal Doxorubicin -LTLD) in Hepatocellular Carcinoma  
(HCC) using standardized Radiofrequency Ablation (RFA)  treatment  time ≥ 45 
minutes  for solitary lesions ≥ 3 cm to ≤ 7 cm.  
Protocol Number  104-13-302 
Countries  Global  
Study Centers  Up to 100 Centers  
Study Period  Approximately 36-month enrollment with estimated 5 -year follow up  
Clinical Phase  Phase III  
Objectives  The pri mary objective  is to compare overall s urvival (OS) between patients receiving 
RFA plus ThermoDox versus RFA alone , using a standardized R adiofrequency 
Ablation (sR FA) treatment dwell  time ≥ 45 minutes . 
 
The s econdary objectives are to compare progression -free survival (PFS) and safety 
between patients receiving sRFA plus ThermoDox versus sRFA alone , using a 
standardized treatment  dwell  time ≥ 45 minutes . 
Study  Design  This is a randomized, double blind, dummy  controlled multicenter trial to evaluate 
the efficacy and safety of ThermoDox plus sRFA compared to sRFA alone using 
standardized treatment  dwell time ≥ 45 min.  for solitary HCC lesions ≥ 3 .0 cm to 
≤7.0 cm. An sRFA treatment for this protocol is defined as the dwell time of ≥ 45 
minutes measured from the first activation of the RFA probe to produce coagulative 
necrosis of target tissue through removal of the RFA probe after the final ablation 
cycle or deployment. This includes the multiple ablation cycles a nd repositioning 
time between cycles for an individual patient.  
 
Eligible HCC patients will have a solitary lesion not amenable to curative resection 
consistent with clinical diagnosis of AASLD classification guidelines and will be 
candidates for RFA. Subjects will be randomly assigned to receive either 
standardized sRFA plus ThermoDox at 50 mg/m2 or standardized sRFA plus a 
dummy infusion  using a standardized RFA dwell time ≥ 45 minutes . Randomization 
and analysis will be stratified by maximum lesion diameter (3 -5 cm versus >  5-7 
cm) and RFA route (laparoscopic, open surgical, percutaneous) . 
 
Screening Period   
Subjects will be evaluated up to 21 days prior to the RFA procedure date to 
establish eligibility for study treatment. Subjects must meet all the study 
inclusion /exclusion criteria prior to randomization to a treatment arm.  
Protocol No.: 104 -13-302   Page 13 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Treatment Period  
Subjects who meet the eligibility criteria will be randomly assigned to either sRFA 
plus ThermoDox or sRFA plus dummy infusion using a web -based randomization 
system. The RFA procedure day will be Day 0 and subjects will return to the clinic 
Day 14 and Day 28 (+/ - 3 days). Subjects with a complete ablation by imaging will 
continue in the follow up period described below.   
 
A subject who has an incomplete ablation is eligible for 1 retreatment procedure 
within 21 days after radiological imaging exam  showing residual disease at Day 28. 
Subjects will be retreated only once with the same RFA equipment and treatment 
assigned at randomization. Baseline safety evaluations must meet the eligibility 
parameters prior to a retreatment. Subjects with a complete ablation after 
retreatment will be followed for both overall survival  (OS) and progression -free 
survival (PFS) . If after 2 ablations the subject has local, distant intrahepatic, or 
extrahepatic HCC , then  the s ubject will be considered a treatment failure and will 
have met the PFS endpoint. The subject is still followed for OS every 3 months  after 
progression .   
 
Among subjects who are not treatment failures, up to five repeat treatments are 
permitted to treat a recurrent lesion  or to treat newly identified local or distant 
intrahepatic lesions at the Investigator ’s discretion after the PFS endpoint is reported 
and with agreement from the Sponsor. The subject must be eligible for retreatment 
consistent with the safety eligibility criteria and will be retreated with the same 
randomized treatment.  
 
Follow up visits  are performed Day 14 and Day 28 (+/- 3 days)  following the 
treatment. Subjects  with bilirubin levels > 2.0 mg/dL  and ≤ 3.0 mg/dL  will return to 
the clinic on Day 7 for  additional safety assessments. Exclusion concomitant 
medications are to be restricted through Day 28 following  study treatment .  
 
Follow -Up Period  
 
Following study treatment, s ubjects will undergo CT or MRI imaging scans  (chest , 
abdomen , and pelvis)   at months 1, 5, 9, 13, 17, 21, and 25 (+/- 2 weeks) , then at 6-
month  interval s (+/ - 2 weeks)  until radiological progression is seen . The same 
imaging modality  and measurement of assessment should be used to characterize 
disease at  baselin e and during follow up for an individual patient. Investigator 
determined r adiological  progression must be observed and recorded prior to 
beginning alternate treatments for HCC. Post -progression treatments will be 
reported and the subject will  continue to be  followed for OS.  
 
To provide surveillance for any late hematologic, cardiac, or liver toxicity, the 
following additional safety assessments will be done:  
• Physical examination, assessment of vital signs, ECGs, CBC with differential, 
serum chemistry, PT/INR and urinalysis at Month 5 , Month 9, and Month 13  
(+/- 2 weeks) or at disease progression, whichever occurs first . 
• LVEF monitoring at Month 13 or at disease progression, whichever occurs 
first. 
• Serum chemistry and PT/INR assessments at Month 17, Month 21, and Month 
25 (+/- 2 weeks)  or at disease progressi on, whichever occurs first.  
Protocol No.: 104 -13-302   Page 14 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
The site will contact all subject s every 3 months after radiological progression to 
document vital status until the subject expires or withdraws consent from the study.  
The follow -up contacts across all clinical sites may be coordinated  using the same 
3-month interval .  
 
Inclusion Criteria  Subjects must meet all of the following criteria to be eligible for the study:  
1. Male or f emale ≥ 18 years of age . 
2. Diagnosed with a single HCC lesion ≥ 3.0 cm but ≤ 7.0 cm in maximum   
diameter  based on diagnosis at screening .  
• Subjects meeting the American Association for the Study of Liver Disease 
(AASLD) criteria may  be randomized without a biopsy, but  will undergo a 
biopsy during the RFA procedure unless contraindicated or unattainable.  
• Subjects not meeting the AASLD criteria for HCC will need a biopsy to 
confirm HCC prior to randomization.  
3. Be an appropriate candidate for receiving RFA  as a medically indicated 
treatment as evaluated by the following factors:  
• The position and accessibility of the target lesion allows for the safe 
administration of multiple ablation cycles or deployments to achieve a probe 
dwell time of ≥ 45 minutes.  
• Not a candidate for surgical resection according to the local guidelines for 
resection and in the Investigator’s judgment.  
4. Child -Pugh Class A without either current encephalopathy or ascites . 
5. Left Ventricular Ejection Fraction (LVEF) ≥ 50% . 
6. ECOG performance status 0 . 
7. Willing to sign an informed consent form, indicating awareness of the 
investigational nature of this study that is in keeping with the policies of the 
institution.  
Exclusion 
Criteria   
Subjects meeting any of the following criteria will be excluded from the study:  
1. Is scheduled for liver transplantation  
2. Expected ablation volume > 30% of total liver volume or removal of 3 hepatic 
segments  
3. More than 1 lesion identified during baseline .  
4. Have previously received therapeutic treatment for HCC outside the study 
protocol or is expected to receive concomitant HCC treatment prior to PFS 
event.  
5. Have serious medical illnesses including, but not limited to, congestive heart 
failure, myocardial infarction or cerebral vascular accident within the last six 
months, or life threatening cardiac arrhythmias.  
6. Have previously received any  anthracycline outside the protocol  
7. Have extrahepatic metastasis.  
8. Have portal or hepatic vein tumor invasion/thrombosis.  
9. Have body temperature >101 ºF (38.3 ºC) immediately prior to study treatment.  
10. Baseline laboratories (repeat lab tests are permitted to evaluate eligibility during 
the Screening Period. Lab results must be within protocol range prior to study 
treatment. ) 
• Absolute neutrophil count < 1500/mm3 
Protocol No.: 104 -13-302   Page 15 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  • Platelet count < 75,000/mm3 
• Hgb < 10.0 g/dL  (unless the hemoglobin value has been stable, the subject 
is cardiovascularly stable, asymptomatic  and judged able to withstand the 
RFA procedure)  
Note: If clinically indicated, subjects may receive platelets or packed RBC 
transfusions and be re -evaluated after condition is treated.  
11. Baseline Chemistry  
• Serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) 
≤25.0 mL/min.  
• Serum bilirubin > 3.0 mg/dL.  
• Serum albumin < 2.8 g/dL.   
12. Have any known allergic reactions to any of the drugs or liposomal components 
or intravenous imaging agents that prohibit the ability to complete the imaging 
requirements.  
13. Are pregnant or breast -feeding. In women of childbearing potential, a negative 
serum pregnancy test is required prior to study treatment.   
14. Women of childbearing potential and men who are not practicing an acceptable 
form of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or 
birth control pills. Women whose partner has or men who have undergone a 
vasectomy must use a second form of birth control).   
15. Have INR > 1.5 times the institution’s upper normal limit (UNL), except in 
subjects who are therapeutically anticoagulated for medical conditions unrelated 
to HCC such as atrial fibrillation. Subjects may be re -screened after condition is 
treated or anticoagulant is withheld.  
16. Have contraindications to receiving doxorubicin HCl.  
17. Are being treated with other investigational agents.  
18. Use of an investigational drug outside this study within 30 days or 5 half -lives, 
whichever is longer, preceding the first dose of study medication.  
19. Have other concurrent malignancy (subjects with treated squamous cell 
carcinoma of the skin or basal cell carcinoma of the skin may be included), 
evidence of extrahepatic cancer from their primary malignancy, or ongoing, 
medically significant active infection.  
20. HIV positive.  
21. NYHA class III or IV functional classification for heart failure.  
22. Evidence of hemachromatosis.  
Trial Drug, Dose 
and 
Administration  
 Oral Premedication : As part of a blinded premedication regimen, subjects will be  
assigned to take 20 mg of oral dexamethasone (ThermoDox arm) or matching 
dummy capsule (Control arm) 24 hours (+/ - 2 hours) prior to the scheduled RFA 
procedure.  
 
Intravenous Premedication:  IV premedication regimen of steroids H1 and H2 
antihistamines (ThermoDox arm) according to local formularies or dummy IV 
premedication of Sodium Chloride 0.9%  or D5W (Control arm) will be administered 
in a blinded fashion. IV medications should be given within 30 minutes (+ 15 min 
window) prior to infusion of study drug.  
 
 
Protocol No.: 104 -13-302   Page 16 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Study Drug Infusion :  A 50 mg/m2 ThermoDox infusion (Therm oDox arm) or 
dummy infusion of Dextrose 5% Solution or Sodium Chloride 0.9%  (Control arm) 
will be administered IV over 30 minutes.  
 
The Sponsor will provide blinded masking materials to maintain the blind and 
unblinded site representative(s) (i.e. pharmacist) will prepare the materials to cover 
IV bags and tubing.  
 
Radiofrequency Ablation : Only FDA approved RFA devices are permitted for this 
trial. RFA requiring a standardized dwell time ≥ 45 minutes will be initiated 15 
minutes (+5 min.) after the start of the study drug infusion with an estimated overall 
procedure time of less than 3 hours. A standardized Radi ofrequency Ablation sRFA 
treatment for this protocol is defined as the dwell time of  ≥ 45 minutes measured 
from the first activation of the RFA probe to produce coagulative necrosis of target 
tissue through removal of the RFA probe after the final ablation cycle or 
deployment. . This includes the multiple ablation cycles and repositioning time 
between cycles for an individual patient . An ablation cycle for this protocol is 
defined as the single activation of the probe or electrode in order to achieve a local 
coagulation necrosis in target tissue. The cycle may  be completed by achieving a 
target temperature in the tissue or a target impedance.  
 
The goal is to ablate  the tumor as well as a 360º 1.0 cm tumor -free margin 
surrounding the tumor. Tumor uptake of ThermoDox is enhanced with a 
standardized treatment dwell time of at least 45 minutes (30 minutes with a 
switchbox). The literature recommends tumors ≥ 3 cm should require at least four 
ablation spheres (if using simple needle electrode) or at least four deployments (if 
using multiple array LeVeen needle electrode). More ablations may be performed at 
the discretion of the operator , however the RFA probe dwell time must reach 45 
minutes . 
 
Pringle maneuver or balloon occlusions are prohibited.  
Sample Size:  The study is designed to detect with 80% power a hazard ratio for OS of 0.67 (33% 
risk reduction) in the ThermoDox (TR) arm compared with the control (PR) arm 
with an overall 1 -sided type  1 error of  0.025. An OS hazard ratio of 0.63 was 
observed in an earlier trial  among H CC patients with a solitary 3 -7 cm lesion 
treated with ≥ 45 minutes of RFA  treatment dwell time. A 3%/year loss to 
survival follow -up rate has been assumed and using a 1:1 treatment allocation 
(TR:PR) of 550 subjects, a target of 197  events (deaths) will be required for the 
primary analysis. Two interim analyses, both f or efficacy and futility, are planned for 
the study. The first is planned after 60% of the target events is reached (118 deaths) 
and the second after 80% of the events has been reached (158 deaths).  
Criteria for 
Evaluation  Efficacy Evaluations:  
Overall survival is defined as the time from the date of randomization to the date of 
death.  I f death is not observed during the study,  survival time will be 
censored at the date of last study follow -up, or the cut -off date,  whichever is 
earlier.  
 
Protocol No.: 104 -13-302   Page 17 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Progression -free survival is defined as the time from the date of rando mization until 
the date of I nvestigator -assessed radiological disease progression or death due to any 
cause. Subjects who are alive with no disease progression as of the analysis cut -off 
date will be censored at the date of the last tumor assessment.    
 
Safety  
All subjects will have adverse event (AE) assessments as well as other safety 
assessments such as physical examinations, vital signs, ECGs, 
echocardiograms/MUGA scans, hematology, clinical chemistry, and urinalysis 
beginning at time of signing of informed consent and continuing through Day 28 
following study drug administration.   
 
To provide surveillance for any late hematologic, cardiac, or liver toxicity, the 
following additional safety assessments will be done:  
 
• Physical examination, asses sment of vital signs, ECGs, CBC with differential, 
serum chemistry, PT/INR and urinalysis at Month 5, Month 9, and Month 13 
(+/- 2 weeks) or at disease progression, whichever occurs first.  
• LVEF monitoring at Month 13 or at disease progression, whichever occurs first  
• Serum chemistry and PT/INR assessments at Month 17, Month 21, and Month 
25 (+/ - 2 weeks) or at disease progression, whichever occurs first.  
  
Subjects with elevated bilirubin levels >  2.0 mg/dL and ≤ 3.0 mg/dL at baseline will 
return to the clinic on Day 7 for additional safety assessments.    
 
Adverse event (AE) assessments will begin at time of signing informed consent  
through Day 28 visit after  the last study treatment . AEs which are assessed as 
possibly, probably, or definitely related to study treatment will be recorded at any 
point during the trial and must be followed until resolution or until the patient is 
clinically stable .  
 
Data Monitoring  
Committee  An independent Data Monitor ing Committee (D MC) will be established by the 
Sponsor to review accumulating safety data at regular intervals throughout the study 
and to monitor trial data integrity . The DMC is responsible for unblinded monitoring 
of subjects with elevated (> 2.0 mg/dL and < 3.0 mg/dL) serum bilirubin levels and 
will advise if any dose or protocol modification is needed to mitigate risk to such 
patients. The D MC will also evaluate the results of preplanned interim efficacy and 
futility analyse s for OS . The D MC’s specific duties as well as statistical monitoring 
guidelines and procedures will be fully described in the DMC Charter.  
Statistical 
Methods   
OS in the I ntent to Treat  populatio n will be compared between the two  treatment 
groups using the stratified log -rank test. The estimate of the hazard ratio and 
corresponding 95%  CI will be provided using a Cox proportional hazards (CPH) 
model including treatment and the stratification factor s (maximum lesion diameter  
[3-5 cm versus >  5-7 cm ] and RFA route [laparoscopic, open surgical, 
percutaneous[ ) in the model. The survival curves will be estimated using Kaplan -
Meier estimates. PFS will be analyzed using the same methodology . 
Protocol No.: 104 -13-302   Page 18 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Sponsor Contact   
Celsion Corporation  
997 Lenox Drive, Suite 100  
Lawrenceville, NJ 08648 ,  USA  
Tel: XXXXXXXXXX  0 Fax: XXXXXXXXXX  
 
 
 
Protocol No.: 104 -13-302   Page 19 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  2. LIST OF ABBREVIATIONS  
Abbreviation  Definition  
AASLD  American Association for the Study of Liver Disease  
ACS  Almac Clinical Services  
AE Adverse Event  
AFP Alpha -Fetoprotein  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
ANOVA  Analysis of Variance  
AST  Aspartate Aminotransferase  
BP Blood Pressure  
BUN  Blood Urea Nitrogen  
CBC  Complete Blood Count  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CIN Contrast -Induced Nephropathy  
CR Complete Response  
CrCl  Creatinine Clearance  
CRF  Case Report Form  
CRO  Contract Research Organization  
CT Computerized Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP3A4  Cytochrome P450 3A4  
D5W  5% Dextrose Solution  
DHR  Distant Hepatic Recurrence  
DLT  Dose -limiting toxicity  
DMC  Data Monitoring Committee  
DSPE -MPEG  N-(methoxypolyethyleneglycolcarbomyl) distearoylphosphatidyl -
ethanolamine  
EC Ethics Committee  
EF Ejection Fraction  
ECG  Electrocardiogram  
EHR  Extrahepatic Recurrence  
FDA  Food and Drug Administration  
GCPs  Good Clinical Practices  
GCSF  Granulocyte Colony -Stimulating Factor  
GGT  Gamma Glutamyl Transpeptidase  
GI Gastrointestinal  
HCC  Hepatocellular Carcinoma  
Hct Hematocrit  
Protocol No.: 104 -13-302   Page 20 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Abbreviation  Definition  
Hgb Hemoglobin  
HIV Human Immunodeficiency Virus  
HT Hyperthermia  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IND Investigational New Drug  
INR International Normalized Ratio  
IR Incomplete Response  
IRB Institutional Review Board  
IRC Independent Radiology Charter  
IRRC  Independent Radiology Review Committee  
IV Intravenous  
LDH  Lactate Dehydrogenase  
LR Local Recurrence  
LTLD  Lyso -Thermosensitive Liposomal Doxorubicin; ThermoDox®  
LTSL  Lyso -Thermosensitive Liposome  
LTFS  Liver Transplant -Free Survival  
LVEF  Left Ventricular Ejection Fraction  
MLC  Metastatic Liver Cancer  
MR Minor Response  
MSPC  1-steroyl -2-hydroxy -SN-glycero -3-phosphoaholine  
MTD  Maximum Tolerated Dose  
MUGA  Multiple gated acquisition  
NCR  No Carbon Required  
NYHA  New York Heart Association  
OS Overall Survival  
PD Pharmacodynamics  
PFS Progression -Free Survival  
PEI Percutaneous Ethanol Injection  
PO Orally  
PR Partial Response  
PRO  Patient -Reported Outcomes  
PT/PTT  Prothrombin Time/Partial Thromboplastin Time  
RBC  Red Blood Cells  
RCW  Recurrent Chest Wall  
RF Radiofrequency  
RFA  Radiofrequency Ablation  
SAE  Serious Adverse Event  
Protocol No.: 104 -13-302   Page 21 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Abbreviation  Definition  
SC Steering Committee  
SD Stable Disease  
sRFA  Standardized Radiofrequency Ablation  with treatment dwell time ≥45 
min. 
CFDA  China  Food and Drug Administration  
SGOT  Serum glutamic -oxaloacetic transaminase  
SGPT  Serum glutamate pyruvate transaminase  
TACE  Transarterial Chemoembolization  
TTLR  Time to Local Recurrence  
TTP Time to Progression  
UA Urinalysis  
UNL  Upper Normal Limit  
WBC  White Blood Cells  
 
Protocol No.: 104 -13-302   Page 22 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  3. INTRODUCTION  
3.1 Overview  
Hepatocellular carcinoma is the sixth most common neoplasm worldwide, but its  very poor 
prognosis makes it the third leading cause of cancer -related mortality, responsible for about 
600,000 deaths annually  (Parkin , et al. 2005) . In the US, 18,000 new cases of HCC are 
diagnosed each year and the incidence is steadily increasing, almost doubling since 1998. 
HCC is commonly diagnosed in patients with longstanding hepatic disease and cirrhosis 
(primarily due to hepatitis C in US and Europe and to hepatitis B in Asia). Mortality and 
hospitalization due to HCC, as well as hospital -related costs (inflation adjusted), increased 
approximately two -fold from 1988 to 2000 (Kim et al. 2005, Thomas and Abbruzzese 2005).  
The incidence of extrahepatic metastases in patients with HCC is generally around 15%, 
which includes such metastases both at the initial diagnosis of HCC or during follow -up 
regardless of treatment (Uka , et al. 2007 ; Yang , et al. 2007).  
 
The Barcelona Clinic Liver Cancer (BCLC) staging and treatment system is widely accepted 
in clinical practice and is also being used in many clinical trials of  new drugs to treat HCC. 
Therefore, it has become the de facto staging system that guides HCC  treatment. The BCLC 
system recognizes three treatments as curative for patients with up to 3 HCC lesions, each  < 
3.0 cm, who have WHO performance status 0 and no more than Child -Pugh class B liver  
impairment . The three curative therapies are surgical resection, liver transplantation, and 
radiofrequency ablation ( RFA) . Patients with HCC lesions ≥ 3 cm are considered incurable. 
Transarterial chemoembolization ( TACE ) is recommended as a palliative treatment for 
patients with WHO performance status 0 and sorafenib is recommended as a palliative 
treatment for patients with WHO performance  status  1-2 (Bruix and Sherman , 2011).  
 
Surgical resection is the mainstay of curative treatment. However, no more than 30% of HCC 
patients are considered suitable for surgical treatment because of tumor size, multifocal 
tumors, vascular invasion, presence of extrahepatic metastases, and/or extensive liver 
impairment. Liver transplantation is an alternative curative treatment, but its application is 
limited by a severe shortage of liver graft donors (Llovet , et al. 2008). Thermal ablation 
modalities such as radiofrequency ablation ( RFA ), microwave ablation, and high -intensity 
focused ultrasound have emerged as important treatment options for such patients in recent 
years.   
 
To sum up, the worldwide HCC population is large and growing. The vast majority, 
including all those with tumors ≥ 3 cm, are incurable. These patients have an unmet need for 
more effective therapies.  
 
3.2 Radiofrequency Ablation (RFA)  
RFA can be applied repeatedly to the same patient to treat multiple tumors at time of 
diagnosis or upon tumor recurrence. There are presently three RFA systems approved by the 
FDA and currently marketed in the U.S for ablation of soft tissue : Angiodynamics , Boston 
Scientific , and Covidien .  Please refer to Appendix IV for equipment specifications.  
 
Protocol No.: 104 -13-302   Page 23 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  In general, RFA systems are comprised of a generator and a family of application -specific 
electrodes containing deployable arrays, saline infusion, or water -cooled needles, all of 
which enable predictable volumes of tissue to be ablated . Ablation is  usually guided by  
computerized tomography (CT), magnetic resonance (MR), or ultrasound. Temperature, 
impedance ( the ratio of voltage to electric current) , and time may be monitored during the 
treatment to allow for accurate control of the energy delivered to the lesion and thus the 
amount of tissue subjected to thermal injury. Both complete and partial responses have been 
observed utilizing RFA and results have been comparable to those obtained with cryotherapy 
(Siperstein , et al.  1997 ; Rossi , et al.  1995 ; Buscarini , et al.  1995). A recent study in China 
(Chen,  et al.  2006) compared RFA and surgery and found no difference in mortality between 
the two treatments . This study suggests that there are clinicians who consider RFA to be a 
viable alternative to surgery. Randomized trials have found that RFA has overall survival 
similar to surgical resection for solitary  tumors < 5 cm (Chen , et al. 2006) and better overall 
survival than percutaneous ethanol injection  (PEI) for 1 -3 tumors < 3 cm (Lin , et al. 2005 ; 
Shiina, et al . 2005) and for 1 -3 tumors < 4 cm (Lin , et al. 2004).  The better performance of 
RFA versus PEI in these HCC studies may relate to RFA’s greater certainty of achieving a 
0.5 to 1 .0 cm tumor -free margin around the tumor boundary.  
 
Approximately 2% of patients undergoing RFA of liver tumors experience major 
complications due to the procedure including intraperitoneal hemorrhage, intrahepatic 
abscesses, gastrointestinal wall perforations , and hemothorax (Berber , et al . 2005 a and 
2005 b). More common minor complications, typically reported in 5% or less of patients, can 
include altered liver function tests, self -limited bleeding, effusions, pain, fever, infection , and 
skin burn (Berber , et al. 2007).  
 
RFA has been used safely in tumors up to 7 cm (Chen , et al. 2004 ; Curley , et al. 2004 ; Dodd , 
et al. 2001 ; Tateishi , et al. 2005).  In the United States, palliative treatments such as 
transcatheter arterial chemoembolization (TACE) and sorafenib are t he standard treatment 
options  for HCC tumors > 5 cm. However,  in this study the combination of RFA and 
ThermoDox is being investigated as a curative treatment for patients with tumors > 5 cm to < 
7 cm  rather than for their palliation.  
 
For HCC tumors > 3 cm, overlapping ablations are required, and this overlapping can miss 
some micrometastases  (Chen , et al. 2004 ; Curley , 2001 ; Dodd , et al. 2001 ; Chen , et al. 2006 ). 
If the efficacy of RFA for HCC tumors ≥ 3.0 cm could be increased, as by an adjuvant, it 
would be a formidable curative modality.  
 
In th is study, RFA treatments will be administered according to the RFA Treatment 
Procedure and device instructions  (Appendix IV) . Investigator s at each site that meet the 
experience qualifications to perform RFA in this study will complete  formal training with an 
accompanying RFA training manual  developed by the Sponsor . All subjects will undergo an 
RFA treatment dwell time lasting ≥ 45 minutes .   
 
Protocol No.: 104 -13-302   Page 24 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  3.3  ThermoDox  
Lyso -Thermosensitive Liposomal Doxorubicin (ThermoDox) is designed for use with RFA 
and consists of the heat -enhanced cytotoxic anthracycline antibiotic doxorubicin within a 
heat-activated liposome. At normal body temperatures  (i.e., 37°C), the product is designed to 
retain doxorubicin with in the liposome as it travels around the body. However, with mild 
heating, (i.e., > 40.0°C), the liposome component of ThermoDox very quickly releases its 
active  doxorubicin  ingredient , which rapidly diffuses into the local tissue.  
 
ThermoDox is administered intravenously and, because it is a liposome, exhibits prolonged  
systemic circulation relative to free (non-liposomal) doxorubicin, with a small portion being 
taken up by mononuclear phagocytic system (MPS) cells in the liver. During 
RFA/ThermoDox therapy, cytocidal heat is directed to a tumor. When heat -sensitive 
liposomes encounter a temperature of 40.0 °C or above, their doxorubicin is released into the 
heated area. The released doxorubicin remains stable up to 90°C (Wood , et al. 2012). So, the 
antitumor activity of ThermoDox/doxorubicin requires mild (≥ 40.0 °C) hyperthermia and 
tissue perfusion to deliver a high concentration of doxorubicin to the tumor margins.  
 
The systemic delivery of ThermoDox in conjunction with local hyperthermia creates a high 
concentration of doxorubicin in the immediate region of the tumor, through the release of 
doxorubicin from ThermoDox liposomes at the site. The temperature isotherms produced in 
this boundary region during RFA should be adequate to activate the release of encapsulated 
doxorubicin deposited locally around the ablation zone and in the tumor vasculature at the 
time of heating. This process extends the region of tissue that can be treated beyond that 
achievable by use of RFA  alone.  
 
Gasselhuber , et al. (2012) published a computational model of doxorubicin concentration in 
liver tumor tissue following combination therapy with ThermoDox and mild hyperthermia, 
(target temperature 43 °C). Their model found a direct correlation between duration of 
hyperthermia and doxorubicin tumor tissue concentration. This finding suggests the 
hypothesis that, when used with ThermoDox, length of heating time can be used to ensure 
delivery of a doxorubicin dose needed to provide a therapeutic effect in tumor tissue. 
Although this study utilized mild hyperthermia, the principle of heat time translating into 
doxorubicin dose is readily applicable to RFA procedures.  
 
A 2013 study in healthy pigs receiving intravenous ThermoDox and RFA of the liver is 
consistent with the hypothesis that doxorubicin target tissue concentration directly covaries 
with duration of hyperthermia  (Swenson, 2014) . Furthermore, fluorescence imaging found 
high doxorubicin concentrations in the margin of the ablation zone and in areas where 
ablations overlapped, supporting the hypothesis that ThermoDox addresses any microscopic 
tumors left behind in the clefts of overlapping ablations.   
 
Haemmerich and Rossmann (2013) conducted a ThermoDox + RFA modeling study. They 
found that the amount  of bioavailable doxorubicin in the tumor margin increases as the actual 
heating time increases. They also found that beginning RFA 15 minutes after starting a 30 -
minute ThermoDox infusion maximizes th e amount  of bioavailable doxorubicin in the tumor 
margin compared to beginning RFA later.  
Protocol No.: 104 -13-302   Page 25 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
In Celsion’s initial  phase III trial, the HEAT Study  (Protocol 104 -06-301), the criterion for 
RFA adequacy was that it ablate each target lesion plus a 360° 1 -cm tumor margin; there was 
no attempt to manage RFA so as to also increase doxorubicin tumor tissue concentration. The 
results of the HEAT Study became available in 2013. The trial achieved the expected level of 
safety. The overall safety profile was consistent with literature reports for liposomal 
doxorubicin and free doxorubicin commercial labels. Other than reversible neutropenia and 
leukopenia, both treatment -related adverse events ≥ grade 3 and serious adverse events were 
rare, affecting < 5% of patients in either arm. However, the primary endpoint of progression 
free survival (PFS) was not met. Patients are still being followed for overall survival (OS).  
 
Post hoc  analysis of the PFS and OS data from the HEAT Study  suggests that ThermoDox 
efficacy for the treatment of single lesions is greatly improved when RFA dwell time is ≥ 45 
minutes. An sRFA treatment for this protocol is defined as the dwell time  of ≥ 45 minutes 
measured from the first activation of the RFA probe  to produce coagulative necrosis of target 
tissue through removal of the  RFA probe  after the final ablation cycle  or deployment. This 
includes the multiple ablation cycles and repositioning time between cycles for an individual 
patient.  Dwell time is relevant for ThermoDox activity because the target tissue and 
surrounding tissue remain at ≥ 40.0°C, even between ablation cycles . This minimum 
effective dose (MED) of RFA dwell time is achieved by administering 4 ablation cycles. In 
this trial, all patients will receive the RFA MED of ≥ 45 minutes dwell time ; in addition, half 
will be randomized to the ThermoDox MTD of 50 mg/m2 and half will be randomized to a 
dummy infusion of D5W  or saline . Randomization and analysis will be stratified by lesion 
diameter (3 -5 cm versus >  5-7 cm)  and RFA route (laparoscopic, open surgical, 
percutaneous)   Lesion diameter was found to be a statistically significant prognostic factor in 
the prior study.  Although nearly all subjects in the prior trial (90.7%; 636/701) received 
percutaneous RFA , this study will also stratify by RFA route for the sake of consistency  with 
the earlier trial’s design . Unlike the prior trial, Child Pugh B  patients will not be enrolled . 
They are much more likely than Child Pugh A patients to die from their underlying liver 
disease , confounding  the effect of anticancer treatment  (Llovet , et al.  2008). In the HEAT 
Study, deaths prior to HCC progression occurred at a rate almost five times higher in Child 
Pugh B patients (19.5%; 8/41 ) than in Child Pugh A patients  (4.1%; 27/660 ).  
 
 
4. OBJECTIVES  
4.1 Primary Objective  
The primary objective  is to compare overall survival (OS) between patients receiving RFA 
plus ThermoDox versus RFA alone, using a standardized R adiofrequency Ablation (sR FA) 
treatment dwell time ≥ 45 minutes.  
 
4.1.1 Measurement  of the Primary Objective  
  
Overall survival will be measured by time from randomization to death from any cause or the 
end of the study. OS will be compared between the treatment arms.  
Protocol No.: 104 -13-302   Page 26 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
4.2 Secondary Objective s 
The secondary objectives are to compare progression -free survival (PFS) and safety between 
patients receiving sRFA plus ThermoDox versus sRFA alone, using a standardized RFA 
treatment dwell time ≥ 45 minutes.  
 
4.2.1 Measurement of Secondary Objective s 
PFS will be measured from the date of randomization to the first date on which one of the 
following occurs , as determined by CT or MRI scan :  
• Death of any cause  
• Treatment failure (inability to achieve CR after two RFA ± ThermoDox treatment 
sessions)  
• Progression due to local tumor recurrence after initial CR  
• Progression due to distant intrahepatic tumor recurrence  
• Progression due to extrahepatic tumor recurrence  
 
 Adverse events (AEs) assessment will begin at time of signing informed consent through 
Day 28 visit following  the last  study treatment. Adverse events which are assessed as 
possibly, probably, or definitely related to study treatment will be recorded at any point 
during the trial and must be followed until resolution or the patient is clinically stable.  
 
Other safety data including physical examinations, vital signs, ECGs, 
echocardiograms/MUGA scans, hematology, clinical chemistry, and urinalysis will be 
assessed through Day 28 following study treatment ..  
 
To provide surveillance for any late hematologic, cardiac, or liver toxicity, the following 
additional safety assessments will be done:  
 
• Physical examination, assessmen t of vital signs, ECGs, CBC with differential, serum 
chemistry, PT/INR and urinalysis at Month 5, Month 9, and Month 13 (+/ - 2 weeks) or 
at disease progression, whichever occurs first.  
• LVEF monitoring at Month 13 or at disease progression, whichever occurs first  
• Serum chemistry and PT/INR assessments at Month 17, Month 21, and Month 25 (+/ - 2 
weeks) or at disease progression, whichever occurs first.  
 
Subjects with elevated bilirubin levels > 2.0 mg/dL and ≤ 3.0 mg/dL at baseline will return to 
the clinic on Day 7 for additional safety assessments.  
 
 
Protocol No.: 104 -13-302   Page 27 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  5. STUDY PLAN  
5.1 Design Overview  
This is a randomized, double blind, dummy  controlled multicenter trial to evaluate the safety 
and efficacy of T hermoDox plus sRFA compared to sRFA alone using standardized 
treatment  dwell time for solitary HCC lesions ≥ 3 .0 cm to ≤ 7 .0 cm. An sRFA treatment for 
this protocol is defined as the dwell time of ≥ 45 minutes measured from the first activation 
of the RFA probe to produce coagulative necrosis of target tissue through removal of the 
RFA probe after the final ablation cycle or deployment. This includes the multiple ablation 
cycles and repositioning time between cycles for an individual patient.  
 
Eligible HCC patients will have a solitary lesion not amenable to curative resection 
consistent with clinical diagnosis by AASLD classification guidelines and will be  candidates 
for RFA. Subjects will be randomly assigned to receive sRFA  plus 50 mg/m2 of ThermoDox  
or sRFA  plus a dummy infusion  using a standardized RFA dwell time ≥ 45 minutes. 
Randomization and analysis  will be stratified by  maximum lesion diameter ( ≥ 3.0 to 5.0 cm 
versus >  5.0 to 7.0 cm)  and RFA route (laparoscopic, open surgical, percutaneous) . 
 
Screening Period   
Subjects will be evaluated up to 21 days prior to the RFA procedure date to establish 
eligibility for the study treatment . Subjects must meet all of the study inclusion/exclusion 
criteria prior to randomization to a treatment arm.  
 
Treatment Period  
Subjects will be randomly assigned to either sRFA plus ThermoDox or sRFA plus dummy 
infusion  using a central  web-based randomization system. The RFA procedure day will be 
Day 0 and subjects will return to the clinic Day 14 and Day 28 (+/ - 3 days).  Subjects with a 
complete ablation by imaging will continue in the follow up period described below.  
 
As part of a blinded premedication regimen, subjects will  be assigned to  take 20 mg of oral 
dexamethasone (ThermoDox  arm) or matching dummy capsule (control arm)  24 hours (+/ - 2 
hours) prior to the scheduled sRFA procedure .  
 
The IV premedication should be administered within 30 minutes (+15 min.) prior to the start 
of the ThermoDox infusion. The following may serve as a guide:  
• Dexamethasone 20 mg IV or dummy infusion of Sodium Chloride 0.9% or 5% 
Dextrose (D5W)  
• Diphenhydramine 50 mg IV  (chlorpheniramine 10 mg IV is permitted) or dummy 
infusion of Sodium Chloride 0.9% or 5% Dextrose (D5W)  
• Ranitidine 50 mg IV or famotidine 20 mg IV or dummy infusion of Sodium Chloride 
0.9% or 5% Dextrose (D5W)  
 
Study drug will be administered IV over 30 minutes  in a blinded fashion . 
• Treatment arm subjects will receive a  50 mg/m2 ThermoDox infusion . 
Protocol No.: 104 -13-302   Page 28 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  • Control arm subjects will receive a dummy infusion of D5W  (250 cc of 5% Dextrose 
solution)  or Saline (250 cc of 0.9%  Sodium Chloride ).  
 
The Sponsor will provide blinded masking materials to maintain the blind and unblinded site 
representative(s) (i.e. , pharmacist) will prepare the materials to cover IV bags and tubing.  
 
Only US FDA approved RFA devices are permitted for this trial. RFA requiring a 
standardized dwell time ≥  45 minutes will be initiated at minute 15 (+5 minutes ) following  
the start of the study drug infusion with an estimated overall procedure time of less than 3 
hours. An sRFA treatment for this protocol is defined as the dwell time  of ≥ 45 minutes 
measured from the first activation of the RFA probe  to produce coagulative necrosis of target 
tissue through removal of the  RFA probe  after the final ablation cycle  or deployment. This 
includes the multiple ablation cycles and repositioning time between cycles  for an individual 
patient . An ablation cycle for this protocol is defined as the single activation of the probe or 
electrode in order to achieve a local coagulation necrosis in target tissue. The cycle may  be 
completed by achieving a target temperature in the tissue or a target impedance.  
 
The goal is to reach a > 45 minute dwell time which can be achieved by employ ing at least 
four ablation cycles or deployments in order to ablat e the tumor as well as a 360º 1.0 cm 
tumor -free margin surrounding the tumor. Tumor uptake of ThermoDox is  enhanced with 
standardized treatment times of at least 45 minutes (30 minutes with a switchbox). The RFA 
literature recommends a minimum of 4 ablation cycles to ablate tumors of ≥ 3.0 cm together 
with a 360° 1.0 -cm margin (Chen , et al. 2004).  
 
According to literature, t umors ≥ 3 cm should require at least four ablation spheres (if using 
simple needle electrode) or at least four deployments (if using multiple array LeVeen needle  
electrode). More  or fewer  ablations may  be performed at the discretion of the operator , 
however the RFA probe dwell time must reach 45 minutes . 
 
The sRFA procedure day will be recorded as Day 0 and subjects will return to the clinic Day 
14 and Day 28 (+/ - 3 days). Subjects with baseline bilirubin levels >  2.0 mg/dL and ≤  3.0 
mg/dL will return to the clinic on Day 7 for additional safety assessments . Subjects with a 
complete ablation by imaging will continue in the follow -Up period described below.   
 
Safety data including physical examinations, vital signs, ECGs, echocardiograms/MUGA 
scans, hematology, clinical chemistry, and urinalysis will be assessed through Day 28 
following study treatment . Adverse events (AEs) will be reported  and exclusion concomitant 
medications are restricted through Day 28 following  the last  study treatment. Adverse events 
which are assessed as possibly, probably, or definitely related to study treatment will be  
recorded at any point during the trial and must be  followed until resolution or the patient is 
clinically stable.   
 
Subjects with a complete ablation by imaging at Day 28 will continue in the follow -up 
period and be followed for PFS and OS .   
 
Protocol No.: 104 -13-302   Page 29 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  A subject who has an incomplete ablation is eligible for 1 retreatment procedure within 21 
days after the radiological imaging exam s howing residual disease at Day 28. Subjects will 
be retreated only once with the same RFA equipment and treatment assigned at 
randomization. Baseline safety evaluations must meet the eligibility parameters prior to a 
retreatment . Repeat screening data will be recorded into the Case Report Form. The second 
ablation must occur no later than 21 days after the first post -ablation scan assessment  at Day 
28. Subjects with a complete ablation after retreatment will be followed both for PFS and for 
OS. If after 2 ablations the subject has local, distant intrahepatic, or extrahepatic HCC , then  
the subject will be considered a treatment failure and will have met the PFS endpoint. The 
subject will be  followed for OS every 3 months .   
 
Among subjects who are not treatment failures, f ive repeat treatments are permitted to treat a 
recurrent lesion or to treat newly -identified local or distant intrahepatic lesions at the 
Investigator’s discretion after the PFS endpoint is reported and with agreement from the 
Sponsor. The subject must be eligible for retreatment consistent with the safety eligibility 
criteria and will be retreated with the same randomized treatment.  
 
Subjects who develop extrahepatic lesions will have met the PFS endpoint and are no longer 
eligible for further protocol treatment ; they  will be followed for OS . 
 
Follow -Up Period  
 
Following study treatment subjects will undergo CT or MRI imaging scans  (chest, abdomen 
and pelvis)   at months 1, 5, 9, 13, 17, 21, 25, then every 6 months (+/ - 2 weeks)  until 
radiological progression is seen . The same imaging  equipment, technique , and measurement 
of assessment  should be used to characterize disease at baseline and during follow up for an 
individual patient. Investigator determined r adiological progression must be observed and 
recorded prior to beginning alternate treatments for HCC. Post -progression treatments will 
be reported and the subject will continue to be followed for OS.  
 
To provide surveillance for any late hematologic, cardiac, or liver toxicity, the following 
additional safety assessments will be done:  
 
• Physical examination, assessment of vital signs, ECGs, CBC with differential, serum 
chemistry, PT/INR and urinalysis at Month 5, Month 9, and Month 13 (+/ - 2 weeks) or 
at disease progression, whichever occurs first.  
• LVEF monitoring at Month 13 or at disease progression, whichever occurs first  
• Serum chemistry and PT/INR assessments at Month 17, Month 21, and Month 25 (+/ - 2 
weeks) or at disease progression, whichever occurs first.  
 
The site will contact all subjects every 3 months after radiological progression to document 
vital status until the subject expires or withdraws consent from the study. These follow -up 
contacts across all clinical sites may be coordinated using the same 3-month interval.  
 
Protocol No.: 104 -13-302   Page 30 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  5.2 Trial Termination  
For reasonable cause, either the Investigator or the Sponsor may terminate this study 
prematurely. Written notification of the termination is required. Conditions that may warrant 
termination include, but are not limited to:  
• The discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the study.  
• Failure of the Investigator to enter subjects at an acceptable rate.  
• Insufficient adherence to protocol requirements (non -compliance).  
• Lack of evaluable and/or complete data.  
• Decision to modify the developmental plan of the drug.  
• A decision on the part of the Sponsor to suspend or discontinue development of 
the drug.  
• Regulatory authority decision.  
 
 
6. STUDY POPULATION  
6.1 Source and Number of Subjects  
Approximately 550 subjects will be randomized at approximately 100 centers worldwide . 
  
6.2 Subject Selection Criteria  
6.2.1 Overview  
This clinical trial can fulfill its objectives only if appropriate subjects are enrolled. The 
following eligibility criteria are designed to select subjects for whom study participation is 
considered appropriate.  All relevant medical and non -medical conditions should be taken 
into consideration when deciding whether this protocol is suitable for a particular subject. 
Eligibility criteria may not be waived by the Investigator and are subject to review in the case 
of a GCP or a regulatory authority audit. Any questions regarding a subject’s eligibility 
should be discussed with the Celsion  medical monitor (see List of Study Representatives at 
the beginning of the protocol ) prior to study treatment.  
 
6.2.2 Inclusion Criteria  
Subjects must fulfill all of the following inclusion criteria to be eligible to participate in the 
study.   
 
Subjects may be randomized without a biopsy if they meet American Association for 
the Study of Liver Disease (AASLD) criteria for the diagnosis of HCC (see Appendix 
VIII ).  Subjects not meeting AASLD criteria for HCC will need a biopsy for confirming 
HCC prior to randomization.  
 
 
Protocol No.: 104 -13-302   Page 31 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  1.  Male or female ≥ 18 years of age  
2.  Diagnosed with a single HCC lesion ≥ 3.0 cm but ≤ 7.0 cm in maximum  diameter  
based on diagnosis at screening .  
• Subjects meeting the AASLD criteria may  be randomized without a biopsy, but 
will undergo a biopsy during the RFA procedure unless contraindicated or 
unattainable.  
• Subjects not meeting the AASLD criteria for HCC will need a biopsy to confirm 
HCC prior to randomization.  
3. Be an appropriate candidate for receiving RFA as a medically indicated treatment as 
evaluated by the following factors:  
• The position and accessibility of the target lesion allows for the safe administration of 
multiple ablation cycles or deployments to achieve a probe dwell time of ≥ 45 minutes.  
•  
• Not a candidate for surgical resection according to the local guidelines for 
resection and in the Investigator’s judgment.  
4.  Child -Pugh Class A without either current encephalopathy or ascites  
5.  Left v entricular ejection fraction (LVEF)   ≥ 50%  
6.  ECOG performance status 0  
7. Willing to sign an informed consent form, indicating awareness of the investigational 
nature of this study that is in keeping with the policies of the institution.  
 
6.2.3 Exclusion Criteria  
Subjects meeting any of the following criteria will be excluded from the study:  
1. Is scheduled for liver transplantation.   
2. Expected ablation volume > 30% of total liver volume or removal of 3 hepatic 
segments  
3. More than 1 lesion identified during baseline.  
4. Have previously received therapeutic treatment for HCC outside the study protocol or 
is expected to receive concomitant HCC treatment prior to PFS event . 
5. Have serious medical illnesses including, but not limited to, congestive heart failure, 
myocardial infarction or cerebral vascular accident within the last six months, or life 
threatening cardiac arrhythmias.  
6. Have previously received any anthracycline outside the protocol.  
7. Have extrahepatic metastasis.  
8. Have portal or hepatic vein tumor invasion/thrombosis.  
9. Have body temperature >  101ºF (38.3ºC) immediately prior to study treatment.  
10. Baseline laboratories (repeat lab  tests are permitted to evaluate eligibility during the 
Screening Period. Lab results must be within protocol range prior to study treatment. ) 
• Absolute neutrophil count < 1500/mm3 
• Platelet count < 75,000/mm3 
• Hgb < 10.0 g/dL (unless the hemoglobin value has been stable, the subject is 
cardiovascularly stable, asymptomatic and judged able to withstand the RFA 
procedure)  
Note: If clinically indicated, subjects may receive platelets or packed RBC 
transfusions and be re -evaluated after condition is treated.  
Protocol No.: 104 -13-302   Page 32 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  11. Baseline Chemistry  
• Serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) ≤ 25.0 
mL/min.  
• Serum bilirubin > 3.0 mg/dL.  
• Serum albumin < 2.8 g/dL.   
12. Have any known allergic reactions to any of the drugs or liposomal components or 
intravenous imaging agents that prohibit the ability to complete the imaging 
requirements.  
13. Are pregnant or breast -feeding. In women of childbearing potential, a negative serum 
pregnancy test is required prior to study treatment.   
14. Women of childbearing potential and men who are not practicing an acceptable form 
of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth 
control pills. Women whose partner has or men who have undergone a vasectomy 
must use a second form of birth control).   
15. Have INR > 1.5 times the institution’s upper normal limit (UNL), except in subjects 
who are therapeutically anticoagulated for medical conditions unrelated to HCC such 
as atrial fibrillation. Subjects may be re -screened after condition is treated or 
anticoagulant is withheld.  
16. Have contraindications to receiving doxorubicin HCl.  
17. Are being treated with other investigational agents.  
18. Use of an investigational drug outside this study within 30 days or 5 half -lives, 
whichever is longer, preceding the first dose of study medication.  
19. Have other concurrent malignancy (subjects with treated squamous cell carcinoma of 
the skin or basal cell carcinoma of the skin may be included), evidence of 
extrahepatic cancer from their primary malignancy, or ongoing, medically significant 
active infection.  
20. HIV positive.  
21. NYHA class III or IV functional classification for heart failure.  
22. Evidence of hemachromatosis.  
 
6.2.4 Potential Risks and Benefits  
Potential Risks  
There are risks to subjects participating in this study. As reviewed in Section s 3.2 and  8.4, 
there are risks associated with the RFA procedure. There are also risks associated with the 
use of doxorubicin HCl.  Based on the clinical experience to date, there does not appear to be 
a substantial unique risk for ThermoDox, but unexpected AEs could occur. The RFA 
procedure itself has a relatively low major complication rate. The safety profile of RFA is 
provided in Section s 3.2 and  8.4. Doxorubicin HCl, the active agent in ThermoDox, is 
routinely given in chemotherapy regimens for multiple cycles after appropriate recovery 
intervals, usually at least 3 weeks . In contrast,  the vast majority (84.8%; 291/343) of subjects 
in the RFA plus ThermoDox arm in the prior trial received only a single dose of 50 mg/m2 of 
ThermoDox.  
 
Protocol No.: 104 -13-302   Page 33 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  The primary toxicities of doxorubicin are myelosuppression and cumulative -dose cardio -
toxicity. The risk of developing impaired ventricular ejection fraction (LVEF) is generally 
proportional to the cumulative exposure. The probability of developing cardiomyopathy 
isestimated to be 1 to 2% at total cumulative dose of 300 mg/m2 of doxorubicin HCL.  (Pfizer 
Doxorubicin HCL Prescribing Information) . The clinical safety profile of ThermoDox as 
observed to date is consistent with the known safety profile of doxorubicin HCl. Subjects in 
this study must have reasonable marrow reserve and adequate cardiac function. Subjects with 
prior doxorubicin exposure are excluded from this study (except in the case of completion of 
treatment or re -treatment ). Expected non -hematological toxicities include cardio -toxicity, 
neuropathy, volume retention, hypersensitivity, mucositis, GI disturbances, nausea , and 
vomiting. Local toxicity in the liver will be carefully evaluated. Renal function will be 
closely monitored with urinalysis. BUN/Urea and creatinine will be monitored as 
nephrotoxicity has been seen in previous animal studies.  
 
The protocol does not require dose reduction in patients with elevated bilirubin. Dose 
adjustment for doxorubicin -containing chemotherapy was based on data from Benjamin , et 
al. (1974). However, an indiscriminate dose reduction based solely on serum bilirubin 
concentrations may not only reduce doxorubicin myelosupression but also the therap eutic 
outcome (Donelli , et al. 1998 ; Johnson , et al.  1986).  In the prior study, subjects  with baseline 
serum bilirubin > 2.0 mg/dL had a higher incidence subsequent grade 3+ hyperbilirubinemia 
and of grade 3+ hepatic failure. However, the greater incidence of hepatic failure consisted of 
a single patient with grade 3 liver failure. Among patients with an elevated bilirubin level at 
baseline, there were no subsequent serious hepatobiliary adverse events except for 2 cases of 
hyperbilirubinemia/blood bilirubin increased . The DMC is responsible for unblinded 
monitoring of subjects with elevated (> 2.0 mg/dL and < 3.0 mg/dL) serum bilirubin levels 
and will advise if any dose or protocol modification is needed to mitigate risk to such 
patients .  
 
Doxorubicin imparts a red coloration to the urine for 1 to 2 days after administration.  
Subjects should be advised that this is expected.  
 
Dose adjustments are recommended in study patients who demonstrate significant 
myelosuppression from the initial dose of ThermoDox.  Guidance on dose adjustment in 
patients receiving additional treatment of study drug is provided in section 8.5.4 of this 
protocol.  Among patients requiring re -treatment after incomplete initial ablation who have 
developed a non-hematologic toxicity > grade 3, no dose modification is required. Instead, 
such subjects will not be re -treated until the severity of the non -hematologic toxicity drops to 
< grade 2.  
 
It is possible that the concomitant use of ThermoDox with RFA may produce larger than 
usual ablation volume post-RFA. Liposomal doxorubicin has been observed to increase 
ablation volume, seemingly by sensitizing the tissue peripheral to the ablation margin  to 
thermal injury and , therefore, effectively reduc ing the temperature threshold for ablation 
(Goldberg , et al.  2002). However, any relative increase in ablation volume is expected to be 
achieved in a controlled manner, since the ThermoDox -related enhanced release of 
doxorubicin will occur in the immediate region surrounding the RFA zone. There are 
Protocol No.: 104 -13-302   Page 34 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  potential risks and benefits from this possibility; however, it has not been an apparent clinical 
problem in subjects treated to date with ThermoDox or in reports of combination of RFA and 
Doxil®, a non -heat-sensitive liposomal formulation  (Goldberg , et al.  2002).  
 
Twenty five to thirty percent of subjects are at risk of developing a "post -ablation syndrome" 
with flu -like symptoms that in most cases appear three to five days after the RFA procedure 
and usually last about five days, although some subjects may remain ill for two to three 
weeks. Subjects with post -ablation syndrome may present with fever, delayed pain, malaise, 
chills, nausea after the procedure, even if only briefly (Dodd, et al. 2005), and transient 
elevation of transaminases. Oral acetaminophen is commonly given to control fever, which is 
the most common symptom. However, treatment of post -ablation syndrome should be based 
on the best judgment of treating physician. All subjects are required to undergo evaluation of 
their vital signs at specified time points after the ablation procedure.  
 
AASLD treatment guidelines permit diagnosis  of HCC  with the use of imaging only and 
without a biopsy for histological or cytologi cal confirmation of disease . Completion  of a 
biopsy  sample  increases risk to subjects with liver disease and therefore is not always 
indicated. However patients who undergo an RFA treatment without a biopsy may be at 
increased risk for undergoing an unnecessary ablation or be at risk for seeding for 
subcapsular or poorly differentiated disease. This risk is minimal and accepted within clinical 
practice guidelines.  
 
RFA has been used safely in tumors up to 7 cm (Chen, et al. 2004; Curley, et al. 2004; Dodd, 
et al. 2001; Tateishi, et al. 2005). In the United States and other local regions, palliative 
treatments such as transcatheter arterial chemoembolization (TACE) and sorafenib are the 
standard of care for HCC tumors > 5 cm. However, in this study the combination of RFA and 
ThermoDox is being investigated as a curative treatment for patients with tumors > 5 cm to < 
7 cm rather than for their palliation. There is risk that RFA is not as effective in the larger 
tumors, however this has not been established. Subjects are eligible to receive palliative 
therapy as medically indicated after progression is observed.  
 
There is a low but definite risk of hemorrhage in the liver or the peritoneal cavity following 
RFA procedure (Berber, et al. 2004 and 2007). After treatment, subjects will be monitored 
closely for at least one day and immediate interventional back -up, i.e., transcatheter arterial 
embolization or surgery, will be available at each study site in accordance with study site’s 
standard of care. Any adverse event must be monitored and recorded.  
 
There is a risk of infusion reactions with ThermoDox since such  reactions to the IV 
administration of liposomal drugs have been previously reported. Severe infusion reactions in 
animals have been reported with ThermoDox in unprotected and less than optimally protected 
animals. A summary of this experience is provided in the non -clinical pharmacology and 
toxicology section of the Investigators brochure (IB).  Celsion’s approach to this has been to 
provide  protection through broad -spectrum prophylaxis using steroids and antihistamine s. 
 
IV contrast should not be administered if medically contraindicated. Subjects that meet the 
protocol’s eligibility criteria may be at risk for contrast -induced nephropathy (CIN) when 
Protocol No.: 104 -13-302   Page 35 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  undergoing  CT with contrast procedures. Investigators must be mindful of the risk factors 
associated with CIN and employ strategies to reduce the risk of CIN. In subjects with 
diabetes or borderline renal function (creatinine > 1.5 mg/dL), special precautions guided by 
the locally accepted medical standards (e.g. , hydration, contrast dose reduction, follow up 
creatinine determination) should be employed. An accepted procedure may include adequate 
intravenous volume expansion with isotonic saline (1.0 – 1.5 mL/kg per hour) for 3 -12 hours 
before the procedure and continued for 6 -24 hours if clinically indicated and based on the 
treating physician’s medical judgment.  
 
Potential Benefits  
It is expected that thermal ablation of a subject’s liver lesion may result in local disease 
control  and improved survival duration . The addition of ThermoDox to this ablation 
procedure has the potential to improve local control by the creation of high local 
concentrations of doxorubicin in the boundary of the ablation margin resulting in increased 
ablation volume and better tumor cell kill in and around the tumor margin. Thus, ThermoDox 
has the potential to enhance the local effects of RFA procedures. However, as an 
investigational product, it is not known at this time if ThermoDox will have a clinical benefit.  
 
 
7. ENROLLMENT AND WITHDRAWAL PROCEDURES  
7.1 Enrollment Procedures  
The Investigator must inform each prospective subject of the nature of the study, explain the 
potential risks, answer questions , and obtain written informed consent from the subject prior 
to performing any study -related screening procedures or assessments. The subject must also 
give consent, in verbal and/or written form, as directed by the ethics committee and/or local 
law. After  written informed consent has been obtained, screening procedures for 
determination of eligibility can be initiated.   
 
Once screening procedures have been completed, the site will use a centralized  
randomization procedure in order to assign subjects to treatment with  RFA plus ThermoDox 
or RFA plus dummy infusion.   
 
7.2 Subject Discontinuation  
Subjects will be discontinued from the study if they withdraw consent.  
 
Following progression, s ites are instructed to contact subjects at 3 -months intervals . At each 
follow -up interval , if contact cannot be made on the first attempt, then the site MUST 
document 3 attempts to contact the subject using phone calls or visits to the physician ’s 
offices. If the site is unable to contact the subject, then a “certified or tracking letter” MUST 
be sent to the subject’s last known residen ce. This method of contact should be attempted at 
3 consecutive follow -up intervals prior to the subject being considered los t to follow up.   
 
If a subject discontinue s from retreatments or from the PFS imaging interval, the patient 
should still be contacted for overall survival until withdraw consent for study participation.  
Protocol No.: 104 -13-302   Page 36 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
7.3 Study Noncompliance  
All instances of noncompliance and all significant protocol violations will be reported to the 
appropriate ethics committee per local regulations. All instances of eligibility violations or 
deviations will be recorded on the case report forms and reported to Sponsor.  
 
If a subject is discontinued from the study due to noncompliance of follow up visits, the 
patient should still be contacted for overall survival until end of study or withdraw consent 
from study participation.  
 
7.4 End of the Study  
The primary analysis will be based on the first 197 events (deaths) observed. Survival 
follow -up will be continued for 5 years after the last patient is randomized, to enhance OS 
evidence for regional or other subgroup assessments.   
 
 
8. STUDY TREATMENT ADMINISTRATION  
8.1 Allocation to Treatment  
Eligible subjects will be randomized through an Interactive Response  Technology (IRT)  
web-based s ystem. Subjects will be randomized in a 1:1 ratio  to either the active  treatment of  
ThermoDox (50 mg/m2) or to the non-active dummy infusion . Both treatment arms will be 
administered in conjunction with standardized RFA  using a ≥  45 minute treatment dwell 
time. The IVR system will advise the unblinded site representative (i.e. pharmacist) the 
treatment arm the subject has been randomized to and the kit number to dispense the pre -
medication (oral capsule) to the subject.  Therefore, randomization must occur at least 24 
hours prior to the scheduled RFA procedure.  
 
A centralized computer -generated randomization scheme has been prepared before the study  
and controlled by the unblinded Sponsor representative . Subjects will be stratified by 
maximum lesion diameter (≥ 3.0 to 5.0 versus >  5.0 to ≤ 7.0 ) and RFA route (laparoscopic, 
open surgical, percutaneous) .   
 
The Sponsor will provide all masking materials to maintain the blind. Each center will have 
identified unblinded representatives (i.e., pharmacist) to prepare the materials and to cover 
IV bags and tubing.  Only designated Sponsor representatives  may be unblinded as well .  
 
8.2 Pre-Medication and ThermoDox Administration  
Please refer to Pharmacy Manual for preparation and administration details. 
ThermoDox is calculated using Boyd ’s formula as indicated in the Manual.  Accurate 
records must be kept regarding calculation and dispensing of study medication for each 
individual subject in the study.  
 
Protocol No.: 104 -13-302   Page 37 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Subjects assigned to the ThermoDox  arm will be assigned a steroid,  H1, and H2 
antihistamine pre-treatment regimen and subjects assigned to dummy infusion arm will 
receive non -active pre -treatment regimen in a blinded fashion .  
 
Oral premedication  is supplied to the site as over encapsulated dexamethasone (20 mg/m2) 
capsules  OR identical dummy capsules . Oral pre -medication is a single dose taken by the 
subject 24 hours (+/ - 2 hours) prior to the scheduled study drug infusion.  
 
The day of the RFA procedure, s ubjects are required to be administered an IV premedication 
regimen according to local medical practice or as noted in the pharmacy manual. The IV 
premedication should be administered within 30 minutes (+15 min.) prior to the start of the 
ThermoDox infusion. The following may serve as a guide:  
• Dexamethasone 20 mg IV  or dummy infusion  of Sodium Chloride 0.9% or 5% 
Dextrose (D5 W) 
• Diphenhydramine 50 mg IV  (chlorpheniramine 10 mg IV  is permitted)  or dummy 
infusion  of Sodium Chloride 0.9% or 5% Dextrose (D5W )  
• Ranitidine 50 mg IV or famotidine 20 mg IV  or dummy infusion  of Sodium Chloride 
0.9% or 5% Dextrose (D5W)  
 
These drugs are to be administered intravenously in the listed order . Intravenous 
premedications are secured using local formulary or matching dummy infusion of Saline or 
D5W. The premedications  should not be mixed in the same bag. The unblinded study 
representative will prepare the pre -medications consistent with the randomized treatment 
arm so that other study personnel  remain blinded .  
 
The total 250 cc volume of ThermoDox (50 mg/m2) or masked dummy infusion is delivered 
in a single 30-minute period through a free flowing IV line. The entire content of the infusion 
bag must be administered .  
 
RFA will be initiated at minute  15 (+5 minutes) following the start of study drug infusion 
and should be completed within 3 hours after study drug infusion initiation. The RFA 
procedure should achieve a dwell time of ≥ 45 minutes, which can be done by employing at 
multiple  ablation cycles or deployments.   
 
 
 
 
 
 
 
 
 
 
 
 
Protocol No.: 104 -13-302   Page 38 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  Figure 1:  Flow chart  of Study Drug Administration in Relation to RFA  
-24 hours  (+/- 2 hrs.)   Subject takes o ral premedication  
             ↓               ↓ 
-30 min . (-15 mins)     Administer IV premedication  
             ↓               ↓ 
  Timepoint  0 minutes     Start IV study drug infusion  
             ↓               ↓ 
   At 15 min. (+5 min)                     Begin  RFA  Procedure  
               ↓                   ↓  
  At 30 minutes   Complete IV study drug infusion  
               ↓                   ↓  
  + 60 minutes         Provide > 45 min. RFA heating time  
             ↓                                                        ↓  
 <  180 minutes                       Complete RFA  Procedure  
 
 
8.3 Use of Radiofrequency Ablation Devices  
Only FDA approved RFA devices including the Covidien switchbox and all manufacturer 
probes for these devices are permitted for this trial. The choice of RFA device s 
(Angiodynamics, Boston Scientific, or Covidien ) will be made at each institution. Physicians  
(Principal Investigator or sub -Investigator) performing RFA may use more than one RFA 
device  at their local institution . However, the same device must be used for all treatments of 
an individual patient.    
 
8.4 Radiofrequency Ablation Procedure  
The goal is to reach a ≥ 45 minute dwell time which can be achieved by employ ing multiple  
ablation cycles  or deployments  in order to ablate the tumor as well as a 360º 1.0 cm tumor -
free margin surrounding the tumor.  Tumor uptake of ThermoDox is enhanced with a 
standardized RFA treatment  dwell  time of ≥ 45 minutes ( ≥ 30 minutes with a switchbox). A n 
sRFA treatment for this protocol is defined as the dwell time  of ≥ 45 minutes measured from 
the first activation of the RFA probe  to produce coagulative necrosis of target tissue  through 
removal of the  RFA probe  after the final ablation cycle  or deployment . This includes the 
multiple ablation cycles and repositioning time between cycles  for an individual patient . An 
ablation cycle for this protocol is defined as the single activation of the probe or electrode in 
order to achieve a local coagulation necrosis in target tissue . The cycle may  be completed by 
achieving a target temperature in the tissue or a target impedance.  
The RFA operator must have experience with performing at least 15 procedures . A minimum 
of 5 prior cases with the device should be documented.   
Protocol No.: 104 -13-302   Page 39 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX   
The standard RFA procedures to achieve adequate dwell time of ≥ 45 minutes must be 
implemented by the sites . 
a. The tumor should be treated with the goal of reaching a > 45 minute dwell time 
which can be achieved by  employing multiple overlapping  ablation cycles 
(according to literature recommend 4 cycles) thus ablating the tumor as well as a 
360° 1.0 cm tumor -free margin around the tumor.  
b. Devices should be operated within manufacturer’s instructions.  
c. A percutaneous, laparoscopic, or open surgical approach may be utilized.  
d. The RFA device operator will activate the RFA generator to initiate tumor tissue 
ablation temperatures at 15 minutes (+5 min.) after the start of the study drug 
infusion .  
e. Enhanced local concentration of doxorubicin and tumor uptake from ThermoDox 
requires at least 45 minutes RFA dwell time. This dwell time is achieved by 
administering multiple ablation cycles, so 4 ablation spheres (if using a simple 
needle electrode) or 4 deployments (if using multiple array LeVeen needle 
electrode) are recommended, but fewer or more may be performed at discretion of 
the investigator provided the dwell time reaches 45 minutes . The RFA literature 
recommends a minimum of 4 ablation cycles to ablate tumors of ≥ 3.0 cm 
together with a 360 º 1.0–cm margin (Chen , et al. 2004). More ablations may be 
performed at the discretion of the operator  (Curley , 2001 ; Dodd , et al. 2001 ; 
Chen , et al. 2006).  
f. Investigators are to follow their chosen RFA device’s particular guidelines for 
overlapping ablation procedures (See Appendix IV ). 
g. Operators should employ strategies for maximal patient safety based on tumor size 
and tumor location  (Rhim , et al. 2001).  
h. The procedure must be completed within  3 hours from the start of the infusion . 
i. The adequacy of ablation will be monitored by ultrasound, MRI, or CT scan 
throughout the procedure in accordance to the site’s standard of practice.  
j. Pringle maneuver or balloon occlusions are prohibited.  
 
RFA will be performed in accordance with RFA Treatment Procedure described in Appendix 
IV and manufacturer’s instructions provided separately .  
 
In order to avoid potential heating or burns to the skin area in contact with the grounding 
pads, handling of the skin area around the pads as well as the number of pads used will be 
determined per the RFA device manual’s instructions. Should the temperature of the ground 
pads rise above 39 °C, the RFA treatment will be discontinued until the temperature returns to 
baseline; additional grounding pads can be employed to avoid skin burns and rising 
temperature.  
 
Protocol No.: 104 -13-302   Page 40 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  8.5 Dose Modifications  
8.5.1 Hepatobiliary Surveillance  
Subjects with an elevated serum bilirubin level (> 2.0 and ≤ 3.0 mg/dL) at baseline will have 
additional safety assesments at Day 7 post -ablation and at any other time the physician deems 
it necessary. These assessments should include a physical exam, vital sign, AE and 
concomitant medications assessment, and a CBC, UA and chemistry laboratory draw.   Grade 
3 – 4 hepatic toxicities are to be followed until resolution.  
 
No dose modification is required for patients with elevated serum bilirubin.  
 
8.5.2 Suggested Management for Hypersensitivity Reactions:  
 
8.5.3 Extravasations  
Infusion of ThermoDox  should be closely monitored for local site reaction. If there are initial 
signs of extravasation, then the infusion must be immediately stopped and continued in 
another vein. Local protocol should be used to treat the affected area. Application of ice over 
the site of extravasation for approximately 30 minutes may be helpful in alleviating the local 
reaction.  
 
8.5.4 Dose Modification for Re -Treatment ONLY  
Among p atients requiring re -treatment after incomplete initial ablation who have developed 
Grade 4 hematologic toxicities, the absolute neutrophil and platelet counts must return to less 
than or equal to grade 1 before re -treatment.   Severity of Symptoms:  Treatment Guidelines:  
Mild Symptoms :  
localized cutaneous reactions such as mild 
pruritis, mild flushing, and mild rash.  
(Grades 0 -1) • Consider decreasing the rate of infusion until 
recovery from symptoms, stay at bedside and 
monitor subject.  
• Then, complete study drug infusion at the 
initial planned rate.  
Moderate to Severe Symptoms :  
any symptom that is not mild (see above) such 
as generalized pruritis, generalized flushing, 
generalized rash, dyspnea, hypotension with 
systolic BP < 80 mm Hg, bronchospasm, 
angioedema and generalized angioedema. 
(Grades 2 -4) • Stop infusion.  
• WITHDRAW FROM STUDY 
TREATMENT  
Anaphylaxis (Any degree of anaphylaxi s): 
(Grade 4)  • Stop infusion.  
• WITHDRAW FROM STUDY 
TREATMENT  
 
Protocol No.: 104 -13-302   Page 41 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  The investigator should follow local/institutional cytokine support or in the absence of local 
guidelines for cytokine support, the investigator may use the “American Society of Clinical 
Oncology 2006 Update of recommendations for the use of white blood cell growth factors: 
An Evidence -Based Clinical Practice Guideline” (Smith et al. 2006). The second ablation 
must occur no later than 21 days after the first post -ablation radiographical imaging  
assessment  at Day 28 . If the patient does not meet the dose modification criteria within the 
timeframe , then patient should be taken off study and treated as clinically necessary.  
 
HEMATOLOGICAL TOXICITY*  
GRADE  ANC  PLATELETS  MODIFICATION  
 
1 1500 -1900  75,000 -150,000  Resume treatment with no dose 
reduction  
2 1000 -<1500  50,000 -<75,000  Wait until ANC ≥ 1,500 and 
platelets ≥ 75,000; redose with no 
dose reduction  
3 500-<999  25,000 -<50,000  Wait until ANC  ≥ 1,500 and 
platelets ≥75,000; redose with no 
dose reduction  
4 <500  <25,000  Wait until ANC  ≥ 1,500 and 
platelets ≥ 75.000; redose at 25% 
dose reduction or continue full 
dose with cytokine support  
*Dose reduction guidelines to investigators for subjects who experience Grade 4 absolute neutrophil counts 
(ANC) or Grade 4 platelet count and require additional ablation due to incomplete ablation  
Among patients requiring re -treatment after incomplete initial ablation who have developed a  
non-hematologic toxicity  > grade 3 , no dose modification is required. Instead, such subjects 
will not be re -treated until the severity of the non-hematologic toxicity drops to < grade 2.  
 
 
9. STUDY MEDICATION  
The Sponsor has prepared a  Pharmacy Manual for further  description of 
premedication and ThermoDox treatment dose preparation. The active pharmaceutical 
ingredient (API) in ThermoDox is doxorubicin hydrochloride for injection, USP. 
Doxorubicin is a cytotoxic anthracycline antibiotic. The investigational product ThermoDox 
combines doxorubicin HC l with a lyso -thermosensitive liposomal carrier. Staff must be 
properly  delegated and trained to handle, prepare , instruct the subject , and administer the 
investigational product.  
 
Protocol No.: 104 -13-302   Page 42 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  9.1 Clinical Supplies  
ThermoDox  will be supplied as 15 mL clear vials containing 2 mg/mL doxorubicin. Multiple 
vial packaging  will be supplied to the sites . The appearance of ThermoDox requires masking 
to maintain the blind of the study, therefore matching dummy  vials will not be supplied for 
the trial.  All treatment medication and premedication will be masked by the pharmacy in 
order to maintain blinding.  
 
The pre-treatment kits will contain over encapsulated Swedish orange opaque size DB AA 
capsules containing Dexamethasone 20 mg  (5) 4 mg tablets  or dummy tablet s.   
 
Intravenous premedications are secured using local formulary or matching dummy infusion 
of Sodium Chloride 0.9% or 5% Dextrose (D5W) . The Sponsor may procure and ship IV 
premedications to site if there are  local regional formular y restrictions.  
 
Only subjects that sign informed consent and are randomized  in the study may receive the 
investigational study medication (ThermoDox  or dummy infusion), in accordance with all 
applicable regulatory requirements.  
 
9.2 Packaging and Labeling  
The vial of ThermoDox for Injection will be labeled Caution: New Drug Limited by Federal 
Law to Investigational Use Only, as presented below (or as required by local regulatory 
authority).  
Randomization identifiers will be placed on active and dummy  pre-medication  kits to guide 
the randomization process.  
 
Sample Label:  
 
 

Protocol No.: 104 -13-302   Page 43 of 103 
Version 2.0, 14 -March -2014   
 
Celsion Corporation   XXXXXXXXXX  9.3 Storage of Study Medication  
ThermoDox must be stored frozen at colder than -60°C as per the manufacturer label . All 
Sponsor supplied investigational product  must be kept  in a secure area with access limited to 
the Investigator and authorized site staff. Storage conditions must be monitored for 
temperature deviations  using a freezer with an appropriate monitoring device.  
 
9.4 Thawing, Stability, and Reconstitution of  ThermoDox  
ThermoDox vials must  be thawed at room temperature for a minimum of 75 minutes  prior to 
reconstitution with 250 mLs of 0.9% Sodium Chloride Injection USP or 250 mLs 5% 
Dextrose Injection USP ( D5W).  The site will remove the number of ThermoDox vials 
necessary for the dose based on the subject’s body surface area (BSA) from  Boyd’s formula.  
Do NOT heat ThermoDox vials to speed up the thawing process.  Accelerated thawing 
techniques are not permitted. After thawing, the vials are stable for 4 hours at room 
temperature (1 5°C to 30 °C).  
 
ThermoDox vials must be thawed and diluted to a final volume of 250 mLs using  sterile 5% 
Dextrose  Injection, USP  (D5W)  or 250 mLs of sterile 0.9% of Sodium Chloride Injection, 
USP ( Saline ). The total volume of 250  mLs is infused over a 30-minute  period through a free 
flowing IV infusion pump .  
 
ThermoDox should be infused at room temperature. Do not heat ThermoDox solutions 
above room temperature during administration.  
 
ThermoDox is supplied sterile and pyrogen free; aseptic procedures should be employed 
during preparation for administration. For detailed storage and preparat ion instructions, refer 
to the P harmacy Manual that is provided to the pharmacist by Celsion.  
 
9.5 Drug Accountability/Disposition of Clinical Trial Supplies  
Drug accountability records are required to be maintained by the site  for all clinical trial 
supplies. Used clinical supplies will be destroyed at the site in accordance with the site’s 
local processes.    
 
Unused clinical supplies will be destroyed in accordance with the site’s regulations only after 
completion of the study supplies reconciliation by the Sponsor’s monitor.  
 
If it is not possible to destroy unused clinical supplies, Celsion  Corporation should be 
contacted in order to make alternative arrangements.  
 
Protocol No.: 104 -13-302       Page 44 of 103 
Version 2.0, Version 14 -March -2014  
 
Celsion Corporation   Confidential  10. SCHEDULE OF STUDY PROCEDURES  
Table 1: Schedule of Study Evaluations  
 
Protocol  
Section  Procedure/Test  Screening
/ Baseline  Treatment Period1 Follow -Up Period  
Procedure Day  
Day 0  Post-Procedure Visits  
(+/- 3 days)  Safety and Efficacy Assessments  
-21 Days  Pre-
Dose  Time 
0 RFA  
+ 15 
min. Post 
RFA  Day 
72 Day 
14 Day 
28 M5, M9, 
M13 or 
Progression3 M17, M21, 
M25  6 Month 
Interval 
after M25  3 Month 
Interval after 
Progression  
Evaluation and Observations             
17.1 Informed Consent  X4            
10.1.3  Demographics and 
Medical History X            
10.1.5  Physical exam  X    X X X X X    
10.1.6  Vital Signs  X5 X5   X5 X X X X    
10.1.7  ECOG 
Performance X            
14 Adverse Event 
Eval.  X  → → → → → → X6 X6    
11 Con. Med. Update  X → → → → → → X     
Treatment Procedures             
8.1 IRT System/ 
Randomization  X7            
8.2 Pre-Medication 
Regimen   X8           
8.2 IV Study Drug 
Infusion    X9          
8.3-8.4 RFA Procedure     X10         
Protocol No.: 104 -13-302       Page 45 of 103 
Version 2.0, Version 14 -March -2014  
 
Celsion Corporation   Confidential  Protocol  
Section  Procedure/Test  Screening
/ Baseline  Treatment Period1 Follow -Up Period  
Procedure Day  
Day 0  Post-Procedure Visits  
(+/- 3 days)  Safety and Efficacy Assessments  
-21 Days  Pre-
Dose  Time 
0 RFA  
+ 15 
min. Post 
RFA  Day 
72 Day 
14 Day 
28 M5, M9, 
M13 or 
Progression3 M17, M21, 
M25  6 Month 
Interval 
after M25  3 Month 
Interval after 
Progression  
Safety Procedures/Lab Tests             
10.1.10  LVEF Monitoring  X11       X11 X11    
10.1.9  12-Lead ECG  X    X   X X    
10.1.11  Serum pregnancy 
test X            
10.1.12  CBC with 
differential  X     X X X X    
10.1.12      Serum chemistry12  X     X X X X X   
10.1.12  PT/INR  X     X X X X X   
10.1.12  Urinalysis  X     X X X X    
Disease Assessment             
10.1.4  Biopsy   X13           
10.1.8  Imaging14 X       X X X X  
15.2.1  Overall Survival15            X15 
 
1.  Retreatment – Subjects are eligible for one retreatment no later than  21 days after the Day 28 imaging scan. The retreatment must be the 
same ( sRFA  + dummy or sRFA +  ThermoDox) as initially administered.  
2.   Day 7 Visit – Only subjects with a total bilirubin > 2.0 but ≤ 3.0 mg/dL must undergo the additional safety visit on Day 7 post -RFA.   
3.   Time of Progression  – Month 13 visit assessments are required  at time of disease progression, whichever occurs first  within the first 13 
months . No further assessments require d after progression is recorded  
4.   Informed Consent – Is required within 28 days prior to  study drug infusion. Informed Consent should be obtained prior to  any study -related 
procedure performed outside standard medical care and required only to evaluate for participation in this trial . 
Protocol No.: 104 -13-302       Page 46 of 103 
Version 2.0, Version 14 -March -2014  
 
Celsion Corporation   Confidential  5.   Vital Signs – Assess screening vital signs prior to randomization and perform a pre-dose assessment the morning of the RFA procedure . 
Post-RFA vital signs should be assessed within 15 minutes after completion of study drug infusion, within 30 minutes and 1 hour (+/- 15 min.) 
after RFA procedure, then every 2 hours (+/ - 15 minutes) until the subject is stable or discharged.   
6.  Adverse Event Evaluation  – Assess adverse events (AEs) through Day 28  following study drug treatment. AEs  after Day 28  evaluated as  
possibly, probably or definitely related to the study drug or the RFA procedure will be recorded at any point during the trial and are to be 
followed until resolution or the patient is clinically stable.  
7.   Randomization – Eligibility criteria must be assessed prior to randomization.  Randomization must occur  at least 24 hours prior to scheduled 
RFA treatment time  to ensure that the oral pre-medication regimen can be started.  
8.  Pre-Medication Regimen - A blinded oral pre -medication capsule is dispensed after randomization with instructions to  take the pre -
medication 24 hours (+/ - 2 hours) prior to the scheduled RFA procedure time. Recommend a reminder phone call be made to the subject the 
morning prior to RFA treatment.  IV premedication (active or dummy infusion ) is administered within 30 mins. ( +15 min.) prior to study drug 
infusion.  
9.  IV Study Drug Infusion – Infusion is intended to be 30 minutes in duration; however, the complete contents of the infusion bag must be 
infused.  
10.  RFA Procedure – 15 minutes (+5 min) after the start of study drug infusion, RFA is to be initiated and is to be completed within 3 hours of 
the start of study drug infusion. RFA procedure should achieve  an RFA  dwell time of ≥ 45 minutes.  
11.  LVEF Monitoring – LVEF monitoring is required at baseline, at Day 28, and at Month 13 or radiologic progression, whichever occurs first . 
Echocardiogram is preferred. MUGA scans are permitted if an echo cannot be completed; however, the same method of measurement  must be 
used to evaluate LVEF in an individual subject.     
12. Liver Function Tests  – Serum Chemistry and PT/INR will be assessed  at baseline, day 14, day 28, month 5, 9, 13 , 17, 21, and 25  or time  of 
progression , whichever comes first.  Patients with elevated bilirubin at baseline will also be assessed at day 7.  
13. Biopsy –Subjects not meeting AASLD diagnosis should have histological confirmation of HCC prior to randomization.  
14. Imaging – CT or MRI imaging  (abdomen, chest, and pelvis)  is required ; however, the same modality used at baseline must be used for all 
further imaging  in an individual subject. Scans must be done within 21 days prior to initial treatment to confirm the presence of an evaluable 
lesion and at Day 28 to evaluate whether a complete initial ablation was achieved. Follow -up imaging will be done at months 5, 9, 13, 17, 21, 
and 25 (+/ - 2 weeks), then at 6 -month intervals (+/ - 2 weeks) until radiologic progression is seen.  For trial purposes, an imaging scan 
demonstrating progression must be recorded before beginning alternative treatment.                      
15. Overall Survival  – All subjects will be contacted every 3 months  after radiological progression  for vital status  reporting.   
 
Protocol No.: 104 -13-302    Page 47 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 10.1 Study Procedures  
10.1.1  Screening Overview  
Written informed consent must be obtained ≤ 28 days prior to initiation of treatment and 
before any procedures specifically for inclusion in the protocol are performed.   
 
Screening assessments will be performed after obtaining informed consent and within 21 
days prior to the initiation of treatment. Screening procedures will include a medical history, 
physical examination, vital signs, ECOG performance  status , adverse event evaluation, 
concomitant medicine update, ECG, ECHO or MUGA  for LVEF measurement , laboratory 
tests, and radiological imaging scans . Screening laboratory procedures may  be repeated to 
assess eligibility parameters during the screening period.  
 
Screening  assessment  will be collected, reviewed and determined to be acceptable by the 
Principal Investigator prior to randomization and must provide sufficient time for the subject 
to begin the pre -medication regimen. Any change in health evaluated by physical exam or 
vital signs should be acceptable  to the Investigator before study treatment is started .  
 
10.1.2  Subject Numbering  
Each subject for whom written informed consent has been obtained will be assigned a n eight -
digit subject  number. The first four digits of the subject  number will be the investigational 
site numbers. The remaining digits will be a number starting with 7001 for the first subject  
enrolled at the site and incrementing by “1” for each sequential subject . 
 
Never reassign patient numbers.   In the event that a subject  withdraws from the study, the 
number assigned to that subject  is retired and the next subject  receives the next sequential 
number.  
 
10.1.3  Demographics and Medical History  
Demographic data  (date of birth, race, and sex ) will be recorded up to 2 1 days prior to study 
drug treatment. Medical history including details of cancer and non -cancer history will be 
collected.  
10.1.4  Disease History and Biopsy  
Data on the current malignancy will include: date of diagnosis and stage of cancer,  
 
The following information must be obtained to confirm HCC:  
1. The date and results of the HCC biopsy.  
2. If a biopsy was not performed or not confirmatory of HCC then  
• Patient must meet AASLD criteria of  
o Hypervascular  with washout in the portal/venous phase (on CT) OR  
o AFP > 200 ng/ml (for detailed description see Appendix VIII) 
• Record the reason why biopsy not performed.  
Protocol No.: 104 -13-302    Page 48 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Subjects may be randomized without a biopsy if they meet American Association for 
the Study of Liver Disease (AASLD) criteria for the diagnosis of HCC (see Appendix 
VIII ).  Subjects not meeting AASLD criteria for HCC will need a biopsy for confirming 
HCC prior to randomization.  
 
10.1.5  Physical Exam  
Physical examination s will be conducted within 2 1 days for eligibility assessment prior to 
randomization. An important component of the physical exam is the accurate measurement 
of height (in cm) and weight (in kg).  All pertinent findings will be recorded on the 
appropriate pages of the CRF.  All changes relative to baseline considered to be clinically 
significant by the Investigator will be reported as AE’s and recorded in the CRF.   
 
The physical exam must be conducted at the following times : 
• Once within 2 1 days of RFA treatment (initial and any re-treatment) . 
• Post RFA prior to  discharge .  
• Day 14 (+/- 3 days)  
• Day 28 (+/- 3 days)   
• Month 5 , Month 9, Month 13  (+/- 2 weeks) or disease progression, whichever 
occurs first  
• Day 7 (+/- 3 days) for subjects with elevated bilirubin   
 
10.1.6  Vital Signs  
Vital signs, which include temperature (in Celsius), blood pressure , pulse rate , and  
respiration must be obtained. Vital signs must be collected in a position that is consistent for 
all time points for each subject and will be collected at the following times : 
• Once within 2 1 days of RFA treatment (initial and any retreatment)  
• Before administration of the investigational product . Note: subjects with a 
temperature or blood pressure outside the eligibility criteria at the pre -dose evaluation 
should NOT  receive treatment with investigational product.  
• Within 15 minutes after completing study drug infusion and after RFA 
completion at 30 minutes (+/ - 15 minutes), 1 hour (+/ - 15 minutes), every 2 hours 
(+/- 15 minutes) until the subject is stable or discharged . 
• Day 14  (+/- 3 days)  
• Day 28  (+/- 3 days)   
• Month 5 , Month 9, Month 13  (+/- 2 weeks) or disease progression, whichever 
occurs first  
• Day 7 (+/- 3 days) for subjects with elevated bilirubin    
 
 
Protocol No.: 104 -13-302    Page 49 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 10.1.7  ECOG Performance Status  
The Investigator will evaluate the patient’s ECOG performance status within 2 1 days prior to 
study treatment . 
 
10.1.8  Imaging  
CT or MRI scans  (Chest, A bdomen and Pelvis)  will be done within 21 days prior to study 
treatment to confirm the presence of an evaluable lesion  and at Day 28 to assess whether a 
complete initial ablation was achieved . Additional i maging will be done at months 5, 9, 13, 
17, 21, 25, then every 6 months (+/ - 2 weeks) until disease progression is seen. The 
following requirements apply to imaging for this study : 
 
• The same modality and technique must be used for all scans of an individual patient . 
• Investigator -determined radiological progression must be documented prior to any 
non-study HCC treatment.  Imaging follow -up should continue for s ubjects with 
clinical evidence of progression until radiological disease progression  is confirmed 
before beginning any non -study cancer treatment.  
• The date of progression will be reported to the CRF.  
 
Once the PFS  endpoint is met, no further CT and MRI scans are required for this study . 
 
For subjects with incomplete ablations who are re -treated a second time and complete 
ablation is achieved, the imaging  studies will continue per protocol with Day 0 set as the date 
of the second ablation procedure. If the lesion cannot be completely ablated after the second 
treatment, then the subject will be considered a treatment failure. Such subjects will continue 
to be followed for adverse events through  Day 28  following the re -treatment ; they will also 
continue to be followed for OS  every 3 months . 
 
10.1.9  ECG  
Acquire an ECG (12 lead with paper printout) at the following time points in relation to study 
drug treatment:  
Pre-Treatment   
• Within 2 1 days prior to study drug infusion  
 
Post-Treatment   
• Once subject  is stable after RFA procedure  
• Day 28 (+/- 3 days)  
• Month 5, Month 9, Month 13 (+/ - 2 weeks) or disease progression, 
whichever occurs first  
 
The Investigator will comment on any changes considered to be clinically significant  and 
report as an AE . All changes considered clinically significant after Day 28 should be reported 
as AEs and recorded in the CRF   if considered possibly, probably or definitely related . 
Protocol No.: 104 -13-302    Page 50 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 10.1.10  ECHO/MUGA Scan  for LVEF Monitoring  
A baseline echocardiogram (ECHO) must be carried out within 2 1 days prior to study 
treatment. Measurements with a MUGA scan are allowed if an echocardiogram cannot be 
performed ; however, the same modality used at baseline must be used for follow -up. Follow -
up scan s must be completed on Day 28 (+/ - 3 days) and at Month 13 or at time progression of 
disease, whichever occurs first .   
 
A decrease of > 10% in resting LVEF that becomes abnormal (lower than the institutional 
lower limit of normal ) should be further evaluated by repeat examination for subjects with  a 
total cumulative doxorubicin of  ≥300 mg/m2.  
 
10.1.11  Serum Pregnancy Test  
Women of child bearing potential must undergo a serum pregnancy test within 21 days prior 
to each administration of study drug . 
 
10.1.12  Laboratory Analytes  
 
Table 2: Laboratory Analytes  
 
Hematology  Clinical Chemistry  Urinalysis  
Hematocrit  Sodium  AST/SGOT  pH 
Hemoglobin  Potassium  ALT/SGPT  specific gravity  
RBC count  Chloride  Alkaline 
Phosphatase  Protein  
WBC count  Glucose  Total protein  Glucose  
Differential WBC 
count  Urea 
nitrogen  Albumin  Ketones  
Platelets  Creatinine  Calcium  Blood  
PT Total 
bilirubin  AFP WBC/HPF  
INR   RBC/HPF  
   Crystals  
 
 
 
 
Protocol No.: 104 -13-302    Page 51 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 The laboratory will perform evaluations of the analytes listed in Table 2 above. Evaluations 
should take place as follows:  
• Within 2 1 days prior to study drug infusion - Repeat laboratory analysis is  
permitted to evaluate eligibility prior to treatment. The repeat analysis results 
must meet the eligibility criteria prior to study drug infusion.  
• Day 14  (+/- 3 days)  
• Day 28  (+/- 3 days)  
• Day 7 (+/ - 3 days) for subjects with elevated bilirubin   
 
Additional hematologic tests (CBC with differential) will be collected at months 5, 9, and 13 
or disease progression, whichever occurs first.  
 
Additional p ost-treatment liver function tests ( Chemistry and PT/INR),  will be collected at 
months 5, 9, 13, 17, 21, and  25 (+/- 2 weeks) or disease progression, whichever occurs first.   
 
10.2  Re-Treatment  
A subject who has an incomplete initial ablation is eligible for 1 retreatment procedure within 
21 days after the scan showing residual disease at Day 28. Subjects will be retreated only 
once with the same treatment assigned at randomization. Baseline safety evaluations must 
meet the eligibility parameters prior to a retreatment. The second ablation must occur  no 
later than 21 days after the first post -ablation scan assessment  at Day 28 . Such subjects will 
continue to be followed for AE s/SAE s through Day 28  after the second study drug 
administration. Subjects with a complete ablation after retreatment will be followed for all 
primary and secondary endpoints . If after 2 ablations the subject has local, distant 
intrahepatic, or extrahepatic HCC , then  the subject will be considered a treatment failure and 
will have met the PFS endpoint. The subject will still be followed for OS.   
 
Among subjects who are not treatment failures, f ive repeat treatments may be permitted to 
treat a recurrent lesion or to treat newly -identified local or distant intrahepatic lesions at the 
Investigator’s discretion after the PFS endpoint is reported and with agreement from the 
Sponsor. The subject must be eligible for retreatment consistent with the safety eligibility 
criteria and will be retreated with the same randomized treatment.  
 
Subjects who develop extrahepatic lesions will have met the PFS endpoint and are no longer 
eligible for further protocol treatment ; they will be followed for OS . 
 
10.3  Unscheduled Assessments and Early Discontinuation  
The Investigator may, at his or her discretion, arrange for a subject to have an unscheduled 
assessment(s), especially in the case of adverse events that require follow -up. If  the subject is 
experiencing an adverse event considered by the Investigator to be possibly related to the use 
of study treatment , then an unscheduled visit should be performed.  
 
 
Protocol No.: 104 -13-302    Page 52 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 If the subject is discontinued from participation within the first year for any reason, the 
Investigator must make every effort to perform Month 13 evaluations as described in Table 
1.  
 
 
11. CONCOMITANT MEDICATIONS  
Subjects may take any medication that is not restricted by the protocol and would not be 
expected to interfere with the intent and conduct of the study. Chronic medications should be 
dosed on a stable regimen, if possible. In the case of medications restricted by the protocol, 
adequate washout times must be observed. Please reference Appendix III for an explanation 
of washout times. All medications (including herbal preparations) at the time of screening 
and within 30 days prior to study drug treatment and other treatments taken by the subject 
during the study and up to 24 hours following treatment, including those treatments initiated 
prior to the start of the study (ICF signing), must be recorded on the Case Report Form.  
 
Subjects should receive full supportive care during the study, including transfusion of blood 
and blood products, and treatment with antibiotics, antiemetics, antidiarrheals and analgesics, 
as appropriate.  
 
Supportive medications may be administered during the course of study for toxicity at the 
discretion of the Investigator. Subjects with myelosuppression may require blood or platelet 
transfusions, filgrastim (or other colony stimulating factors), or other supportive care 
medications, all of which may be administered at the Investigator’s discretion. Antiemetics 
may be administered to control nausea and vomiting, and antidiarrheals may be prescribed 
for diarrhea.  
 
Liposomal drugs (Abelect ™, Ambisome ™, Nyotran ™, etc.), or lipid -complexed drugs 
(fentanyl, etc.) or intravenous fat emulsions could change the pharmacokinetic profile of 
ThermoDox and should not be administered to study subjects while on the trial.  Intravenous 
fat emulsions, except propofol, should be prohibited as instructed in Appendix III.  
 
Doxorubicin is a substrate of CYP3A4. The following medications are prohibited from the 
specified time -point before the first dose of study drug treatment:  
• Other anti -cancer therapy should not be given until Investigator determined 
radiological disease progression, at minimum 30 days after the last study 
treatment , or withdrawal from the study. Subjects who receive concurrent anti -
cancer therapy will be discontinued from the study . 
• Any other investigational drugs, from 30 days or 5 half -lives, whichever is longer, 
prior to the first dose of study treatment until Investigator determined radiological 
progression. Subjects should not start another investigat ional  drug without 
discussion with the medical monitor. If an investigational drug is initiated , it must 
be a minimum of 30 days after the last study drug treatment (except in re -
treatment)  
Protocol No.: 104 -13-302    Page 53 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 • Inducers and inhibitors of CYP3A4 – these may alter the metabolism of 
ThermoDox, as the drug is a substrate for CYP3A4. CYP3A4 inducers and 
inhibitors that are prohibited from screening through 30 days after the last study 
treatment can be found in Appendix III Prohibited Medications;  
• Certain herbal supplements are prohibited as listed in Appendix III.  
 
 
12. ASSESSMENT OF EFFICACY  
12.1 Primary Endpoint: Survival  
All patients will be monitored for survival by recording their visits during routine follow up 
for response to treatment.  The visits are scheduled to occur every four months from the first 
imaging study confirming complete ablation until month 25 or radiological progression, 
whichever comes first.  If patients have not demonstrated radiological progression at month 
25 then the imaging visit schedule is reduced to every six months until progression .   
Survival is confirmed at every imaging visit.  
 
Once radiological progression is confirmed then follow up for overall survival is required.  
Sites are required to confirm contact with the subject during either a clinic visit or a 
telephone contact every three months.  It is expected that subject follow up will be about five 
years.  
 
12.2 Secondary Endpoint: Progression Free Survival  
The protocol incorporates  modified RECIST (mRECIST) developed for HCC clinical 
research as a basis to evaluate tumor response.  The mRECIST enables assessment of overall 
response by taking into account target lesion response, and presence or absence of new 
lesions.  A separate imaging manual and imaging training program has been developed for 
this study in order to ensure uniformity in imaging technique and imaging review  in 
accordance with mRECIST .  
 
12.3 Baseline Assessment  
The baseline assessment must include a comprehensive evaluation of the chest, abdomen and 
pelvis.  The HCC tumor identified on the eligibility scan should be defined as target lesion 
and its longest diameter should be measured on the contrast -enhanced CT or contrast -
enhanced MRI scan. This measurement should reflect the overall longest tumor diameter, 
regardless of the presence of internal areas of spontaneous necrosis. In the study protocol, 
intermediate size is defined as a tumor lesion larger than 3.0 cm but not exceeding 7.0 cm in 
longest diameter. Since the study will recruit patients with solitary tumors and no evidence of 
vascular invasion or extrahepatic spread, the eligible size HCC lesion detected on the 
eligibility scan is expected to be the only target lesion. No additional target or non -target 
lesions should be detectable on the eligibility scan to allow enrollment in the study  
Protocol No.: 104 -13-302    Page 54 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 12.4 Target Lesion Response and Local Recurrence  
The image acquisition protocols used for any post -baseline assessments should be consistent 
with the protocol used for the baseline eligibility scan .   Baseline images for treatment 
eligibility will be confirmed centrally before RFA  treatment.  Investigator determined 
radiological confirmation of complete ablation will occur at one month post RFA. If initial 
RFA is incomplete then a second, and final, attempt may be made for a complete ablation for 
subject to stay on protocol.  Once a complete ablation is confirmed then patients are 
monitored radiologically until progression.  The imaging interval will be every four months 
until month 25 then every six months thereafter.  No imaging studies are required once 
progression is confirmed.  
 
The disappearance of any intratumoral  enhancement in the target tumor lesion after treatment 
with study treatment  will be classified as complete response (CR), while the persistence of 
any areas of intratumoral enhancement consistent with residual viable tumor will be 
considered as incomplete response (IR). Failure to achieve a CR after two RFA ± 
ThermoDox treatment sessions will be classified as treatment failure. Tumor recurrence 
detected within or around the target lesion after having achieved initial CR will be classified 
as local recurrence. Tumor recurrences will be defined as local if they are located 1 cm or 
less from the ablation margin  
 
12.4.1  Response Criteria for Assessing Index  Lesion  
PFS will be measured from the date of randomization to the first date on which one of the 
following occurs :  
 
• Death of any cause  
• Treatment failure (inability to achieve CR after two RFA ± ThermoDox treatment 
sessions)  
• Progression due to local tumor recurrence after initial CR  
• Progression due to distant intrahepatic tumor recurrence  
• Progression due to extrahepatic tumor recurrence  
 
Disease progression will be assessed locally at each study site . CT or MRI scans (chest , 
abdomen , and pelvis) will be done at baseline and post -treatment at months 1, 5, 9, 13, 17, 
21, 25, then every 6 months (+/ - 2 weeks) until radiological progression is seen.  The 
definitions below will be used to assess disease progression. All i maging scans must be 
submitted centrally . Progression must be documented prior to any non -study HCC treatment.  
 
  
Protocol No.: 104 -13-302    Page 55 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Table 3: Radiological Progression Definitions  
 
Complete Response 
(CR):  Complete disappearance of viable tumor on follow -up scan (Day 
28) when compared to the pretreatment images.  The ablation zone 
is defined radiographically as a homogeneous, avascular, non -
enhancing, sharply marginated ablation site following RFA 
evaluated on both arterial and portal venous phases and complete 
disappearance of the lesion. Ablation zones that are larger than the 
tumor (including a rim of surrounding liver parenchyma) are 
intentionally created to reduce the risk of local recurrence and are a 
much better predictor of actual complete ablation than is an ablation 
zone that is only equal in size to the native tumor.  
 
Incomplete Response 
(IR):  Incomplete Response (IR): Any image -detected residual viable 
tumor at or within 1 cm of the ablation zone on Day 28  scan 
following initial ablation  therapy that is smaller in size compared to 
pre-treatment scans, irrespective of the size of the zone of ablation.  
Incomplete responses will be allowed to be re -treated once.    
Local Recurrence 
(LR):  Local recurrence (LR): Recurrence of viable tumor at or 
contiguous (within 1 cm) to the site of a prior ablation in the liver 
based on meeting one of any of the specific imaging criteria and 
features listed below when comparing the recent imaging (latest) to 
the reference imaging ( Day 28  post-RFA, assuming complete 
treatment on Day 28  scan):  
• New soft tissue attenuation nodules  that abnormally enhance  
and washout following intravenous contrast administration.  
• On subsequent scans at time points longer than 4 -6 weeks 
after RFA: Presence of a measurable increase (at least 10 
mm) in size of the abnormally enhancing nodular soft tissue 
component within or adjacent to the treated tissue, as 
compared with baseline scan at approximately Day 28  post-
RFA.   
• A new HCC lesion or nodule signifying local recurrence is 
defined as a hypervascular lesion or nodule with abnormal 
enhancement and washout as defined above, and measuring 
greater  than 10 mm in any axial dimension.  
• A lesion that does not show the prior typical features of 
HCC, but demonstrates serial enlargement of at least 10mm.  
  
Distant Hepatic 
Recurrence (DHR):  Development of a new lesion (meeting the criteria described above 
for a new lesion) in the liver at a site greater than 1 cm from a prior 
ablation site, compared with nadir.  
Protocol No.: 104 -13-302    Page 56 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Extrahepatic 
Recurrence (EHR):  Appearance of a new lesion outside of the liver.   Note: extrahepatic 
HCC lesions may not demonstrate the same enhancement criteria as 
indicated for intrahepatic lesions; however, they should be 
unequivocally malignant and new since nadir.  There are no size 
criteria.  
Unable to Evaluate 
(UE):  A lesion present at baseline which was not measured or which was 
unable to be evaluated leading to an inability to determine the status 
of that particular tumor for the time point in question.  
Not Done (ND):  Scans were not performed at this time point to evaluate the lesions.  
Equivocal (EQ)  A new liver lesion that is smaller than 1 cm in longest diameter OR 
fails to show a typical enhancement profile should be considered as 
equivocal and not conclusive for disease progression. Such lesions 
can be diagnosed as HCC by evidence of either a change in 
enhancement pattern OR at least 1 -cm interval growth in 
subsequent scans.  
 
 
 
Table 4: Overall responses for possible combinations of tumor responses in the target 
lesion with or without the appearance of new intrahepatic or extrahepatic lesions.  
 
Target  
Lesion  Distant Intrahepatic 
Recurrence  Extrahepatic Disease  Overall Response  
CR No No CR 
IR* No No Treatment Failure  
IR* Yes No Progression  
IR* No Yes Progression  
Local Recurrence  Yes or No  Yes or No  Progression  
Any Yes Yes or No  Progression  
Any Yes or No  Yes Progression  
*After 2 RFA +/- ThermoDox  treatment sessions within 21 days after Day 28 radiological 
examination.  
 
Protocol No.: 104 -13-302    Page 57 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 13. ASSESSMENT OF SAFETY  
Safety data will be tabulated for all subjects who were treated under the study protocol in 
either treatment group and will include vital signs, laboratory parameters, ECG, 
echocardiograms/MUGA, and adverse events. The Principal Investigator is responsible for 
recognizing and reporting adverse events during the conduct of the trial.  
 
A Data Monitor ing Committee ( DMC ) will evaluate safety data on an ongoing basis at 
regular intervals during subject accrual and follow -up. The DMC is responsible for unblinded 
monitoring of subjects with elevated (> 2.0 mg/dL and < 3.0 mg/dL) serum bilirubin levels 
and will advise if any dose or protocol modification is needed to mitigate risk to such 
patients.  The Sponsor is responsible to report relevant SAEs to applicable local, national, 
and/or international regulatory body.  
 
 
14. ADVERSE EVENTS  
An adverse event is defined as any unfavorable and unintended sign, including an abnormal 
laboratory finding, symptom, or disease temporally associated with the use of an 
investigational product, whether or not related to the investigational product. This includes 
any occurrence that was new in onset or aggravated in severity or frequency from the 
baseline condition. Adverse events (AEs) assessments will begin at time of signing of 
informed consent and will continue through  Day 28  following study drug administration . 
AEs which are assessed as possibly, probably, or definitely related to study drug must be 
followed until resolution or until a stable clinical endpoint is reached.  
 
Other safety data including physical examinations, vital signs, ECGs, 
echocardiograms/MUGA scans, hematology, clinical chemistry, and urinalysis will be 
assessed through Day 28 following study treatment .  Subjects with an elevated serum 
bilirubin level (> 2.0 and ≤ 3.0 mg/dL) at baseline will have additional safety assessments  at 
Day 7 post -ablation and at any other time the physician deems it necessary .  
 
To provide surveillance for any late hematologic, cardiac, or liver toxicity, the following 
additional safety assessments will be done:  
• Physical examination, assessment of vital signs, ECGs, CBC with differential, serum 
chemistry, PT/INR and urinalysis at Month 5, Month 9, and Month 13 (+/ - 2 weeks) or 
at disease progression, whichever occurs first.  
• LVEF monitoring at Month 13 or at disease progression, whichever occurs first  
• Serum chemistry and PT/INR assessments at Month 17, Month 21, and Month 25 (+/ - 2 
weeks) or at disease progression, whichever occurs first.  
 
The condition which is detected by the diagnostic procedure conducted to test the efficacy of 
the investigational agent is not considered an AE.   
 
Protocol No.: 104 -13-302    Page 58 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Symptoms or clinically significant laboratory or instrumental (e.g., electrocardiographic) 
abnormalities of a pre -existing disease, such as cancer or other disease, should not be 
considered an AE. However, occurrence of new symptoms or laboratory or instrumental 
abnormalities, as well as worsening of pre -existing ones, are considered AEs.  
 
Abnormal results of diagnostic procedures, including laboratory test abnormalities, are 
considered adverse events if they result in:  
• Treatment or any other therapeutic intervention.  
• Further diagnostic evaluation (excluding a repetition of the same procedure to 
confirm the abnormality).  
• Associated clinical signs or symptoms that would have a significant clinical 
impact, as determined by the Investigator .  
 
Any untoward medical event that occurs from the time of signed informed consent to the 
time immediately prior to the first study drug administration will be reported as a “predose 
event” in the Medical History CRF.  
 
All adverse events  that occur following study drug treatment  will be documented on the AE 
CRF with indications of onset, duration, severity (NCI Common Terminology Criteria for 
Adverse Events), presumed relationship to study medication/RFA (not related, unlikely, 
possibly, probably, definit ely), remedial actions taken, and outcome.  
 
An adverse event will be considered associated with the use of the study drug/RFA if the 
attribution was possibly, probably, or definitely.  
 
All subjects will be encouraged to report adverse events spontaneously or in response to 
general, open -ended questioning. All adverse events which are assessed as possibly, 
probably, or definitely related to study drug are to be followed up until resolution or the 
patient is clinically stable .   
 
Adverse events will be graded according to NCI Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03  (See Appendix IX).  
 
14.1 Laboratory Test Results  
Clinically significant laboratory or instrumental (e.g., electrocardiographic) abnormalities of 
a pre -existing disease, such as cancer or other disease, should not be considered an AE. Any 
laboratory test result considered by the Investigator to be unusual , associated with clinical 
signs and/or symptoms , and clinically significant should be reported as an adverse event 
(clinically significant adverse events include those which require an intervention). Grade 3 
laboratory abnormalities meeting the above description should be recorded as AE s. All grade 
4 abnormal laboratory results must be recorded as AE s.  
 
Significant abnormal values occurring during the trial will be followed until repeat test 
results return to normal, stabilize, or are no longer clinically significant. Any positive 
Protocol No.: 104 -13-302    Page 59 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 pregnancy test result must be repeated , study treatment withdrawn, and any pregnancy must 
be followed to term.   
 
14.2 Overdose  
Any instance of overdose (suspected or confirmed) must be communicated to the medical 
monitor within 24 hours of knowledge and be fully documented as a serious adverse event.  
An overdose should be evaluated by the P rincipal Investigator  and potentially reported as an 
unanticipated problem to the site ’s IRB according to local requirements.  
 
An o verdose in which signs, symptoms, or abnormalities meet  the definition of an adverse 
event or serious adverse event must be fully documented and reported consistent with AE 
and SAE reporting guidelines. Details of any signs or symptoms and their management must 
be recorded in the CRF.  
 
14.3 Non-Serious Clinical Adverse Events  
A non-serious adverse event  is any AE that does not meet the criteria listed in section 14.4 
for a serious AE or the outcome (i.e., subject treatment, life -threatening condition, 
hospitalization, recovery) cannot be determined with the information provided.  
 
For detailed description of relationship of AE to study treatment refer to Appendix V.  
 
14.4 Serious Adverse Events (SAE)  
Serious adverse events are defined as any untoward medical occurrences that at any dosage 
results in one or more of the following:  
• Death.  
• Is immediately life -threatening, (i.e., presented an immediate risk of death at the 
time of the adverse event, not an adverse event that hypothetically might have 
caused death if it were more severe).  
• Requires or prolongs inpatient hospitalization.  
• Causes persistent or significant disability/incapacity.  
• Is a congenital anomaly/birth defect.  
• Significant medical event  that requires intervention to prevent one of the above  
outcomes listed in the above definition   
 
Any SAE, which occurs after a subject has signed consent and until Day 28  following  last 
study drug administration, whether or not related to study treatment, must be reported to 
Pharmacovigil ance immediately (within 24 hours of knowledge of the event) via telephone, 
facsimile or email. If initially reported via telephone or email, this must be followed up by a 
facsimile of the written SAE report (within 24 hours of the initial telephone report).  
 
Country specific reporting requirements apply. For example, all China local SAEs during the 
study must be reported within 24 hours to the CFDA.  
 
Protocol No.: 104 -13-302    Page 60 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 14.4.1  Definition of Life -Threatening Adverse Experiences  
An adverse experience is life -threatening if the subject is at immediate risk of death from the 
event as it occurred; i.e. , it does not include a reaction that, if it had occurred in a more  
severe  form, might have caused death. For example, drug -induced hepatitis that resolved 
without evidence of hepatic failure would not be considered life threatening, even though 
drug-induced hepatitis can be fatal.  
 
14.4.2  Definition of Disabling/Incapacitating Experiences  
An adverse experience is incapacitating or disabling if the experience results in a substantial  
and/or permanent disruption of the subject’s ability to carry out normal life functions.  
 
14.4.3  Reporting of SAEs  
Any serious event, including death from any cause that occurs up to one month following last 
study treatment  administration , whether or not related to the investigational drug  or RFA , 
must be reported to Pharmacovigilance immediately (within 24 hours) via telephone, fax, or 
e-mail.   
 
If initially reported via telephone or e -mail, this must be followed -up by a written faxed 
report to be submitted within 24 hours of the initial report.   
 
 
Pharmacovigil ance ( SAE ) contact phone numbers:  
 
InVentiv Pharmacovigilance  
 
Region  North America  Mainland China  Europe & Rest of 
World  
Fax (SAE 
reporting)  XXXXXXXXXX  XXXXXXXXXX  XXXXXXXXXX  
Email  XXXXXXXXXX  (NA)   
XXX XXXXXXXXXXXXXXXXXXX XXXXXXX  (ROW/Asia Pac)  
 
 
Initial Reports  
Within 24 hours of the site’s knowledge of a serious adverse event:  
• Complete a Serious Adverse Event Report Form (SAER), sign it, and fax it  to the 
Pharmacovigil ance using the designated fax transmittal form.   
• Place the initial version of SAER in the subject’s file.  
 
 
Protocol No.: 104 -13-302    Page 61 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Follow -Up Reports  
New information received spontaneously or by request of the Medical Monitor or Safety 
Surveillance : 
 
Within 48 hours of the receipt of new information:  
• Complete a new SAER with the new information. Sign and fax the form to 
Pharmacovigil ance.   
• Fax copies of supporting documents (e.g., hospital discharge summaries, lab test 
results with normal ranges, autopsy or biopsy reports) to Pharmacovi gilance.  
• Place the follow -up version of the SAE and all supporting documentation in the 
subject’s file.  
 
Final Report  
Within 48 hours of the receipt of final information:  
• Determine that there is no further information available and this update may be 
considered final.  
• Complete a new SAER form with the new and final information. Sign and fax the 
form to Pharmacovigil ance. As above, send copies of any additional supporting 
information.  
• Place this version of the final SAER into the subject’s file.  
 
It is imperative that Pharmacovi gilance be informed within 24 hours of a serious adverse 
experience (including overdose with clinical effect, which is considered an SAE) so that 
reporting to the FDA and other regulatory agencies can be met within the required time 
frame (7 or 15 calendar days).   
 
Because of the need to report to health authorities all serious adverse experiences in a timely 
manner, it is vitally important that an Investigator report immediately any adverse 
experiences, which would be considered serious, even if the Investigator does not consider 
the adverse experience to be clinically significant or drug/RFA -related.  
 
Should the Investigator become aware of an SAE (regardless of relationship to study drug) 
that occurs while the subject is on the study, the SAE must be reported in accordance with 
the procedures specified in this protocol.  
 
If the subject is withdrawn less than 28 days after study drug treatment, any SAEs which 
occur within 28 days after study drug treatment must be reported in accordance with the 
procedures specified in this protocol.   
 
All serious adverse events that are assessed as possibly, probably, or definitely related to 
study drug are to be recorded at any point during the trial and followed until either: the 
adverse event resolves, the adverse event stabilizes, the adverse event returns to baseline 
Protocol No.: 104 -13-302    Page 62 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 values (if a baseline value is available), or it is shown that the adverse event is not 
attributable to the study drug or study conduct.  
 
14.5 Other Events  
If a female subject becomes pregnant during the study, follow -up of the outcome of the 
pregnancy and any postnatal sequelae in the infant is required. Pregnancies are not 
considered SAEs but are considered immediately reportable (within 24 hours) and are to be 
documented on the Pregnancy Report form.  
 
Medical and scientific judgment is to be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as for important medical events that were not 
immediately life -threatening or did not result in death or hospitalization but are jeopardizing 
the subject or require intervention to prevent one of the outcomes listed above.  
 
 
15. STATISTICS  
A Statistical Analysis Plan (SAP) that includes a more technical and detailed description 
(including templates for Tables, Listings, and Figures) of the planned statistical summaries 
and analyses will be prepared.  
 
15.1 Study Populations  
The safety and efficacy study populations will be defined as follows:  
• Intent -to-Treat (ITT) population: This population includes all randomized subjects 
and is the primary population for subject characteristics and all efficacy parameters. 
All analyses using this population will be based on the treatment to which each 
subject was randomized.  
• As-Treated (AT) population: This population includes all subjects who actually 
received at least one application of RFA plus ThermoDox (TR) or RFA + dummy 
infusion (PR).  This population will be used for the safety analyses. All analyses 
using this population will be based on the treatment actually received.  
 
15.2 Study Endpoints  
15.2.1  Primary Endpoint – Overall Survival (OS)  
Overall Survival is the primary endpoint of this study and is defined as the time (in months) 
from the date of randomization to the death date. In the absence of death confirmation or for 
subjects alive as of the OS cut -off date, survival time will be censored at the date of last 
study follow -up, or the cut -off date, whichever is earlier.  
 
The OS cut -off date used for the primary analysis will be based on the observations of the 
197th death in the study. With the OS cut -off date being event driven, for operational 
Protocol No.: 104 -13-302    Page 63 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 efficiency, the cut -off date for all other study endpoints (e.g. , PFS) will be fixed at close 
proximity of the OS cut -off date, when the milestone is nearing completion.  
15.2.2  Secondary Endpoints  
15.2.2.1  Progression -Free Survival (PFS)  
Progression -free survival is defined as the time (in months) from the date of randomization 
until the date of the Investigator -assessed radiological disease progression or death due to 
any cause.  Subjects who are alive with no disease progression as of the analysis cut -off date 
will be censored at the date of the last tumor assessment. Subjects who receive non -study 
cancer treatment before disease progression, or subjects with clinical but not radiologic 
evidence of progression will be censored at the date of the last evaluable tumor assessment 
before the non -study cancer treatment is initiated. If a subject undergoes a liver transplant or 
liver resection before progression is observed, then the PFS for this subject will be censored 
on the date of last assessment without documented progression prior to the procedure. 
Treatment failures (subjects with incomplete ablations after two RFA procedures) will be 
considered to have met the PFS endpoint and the date of the Day 28 assessment following the 
2nd ablation procedure  will be used as the progression date. Additional censoring rules details 
will be outlined in the SAP.  
 
15.3 Statistical Analysis  
15.3.1  Subject Disposition, Baseline and Treatment Characteristics  
15.3.1.1  Subject Disposition  
The number of subjects in each study population and the reasons for exclusion, along with 
any randomization and/or stratification errors will be summarized. In addition, subjects that 
discontinue study treatment or study follow -up will also be summarized, along with reasons 
for study discontinuation.  
15.3.1.2  Subject Baseline Characteristics  
Subject characteristics at Baseline will be summarized in frequency tables or with summary 
statistics for continuous variables.  
15.3.1.3  Study Treatment  
The study treatment administration and compliance profile will be summarized descriptively.  
15.3.1.4  Non-Study Treatment in the Study Follow -up Period  
The number, type, and extent of use of non -study cancer treatment after study treatment 
discontinuation will be summarized.   
15.3.2  Efficacy Analyses  
15.3.2.1  Primary Efficacy Analysis  
OS in the ITT population will be compared between the 2  treatment groups using the 
stratified log -rank test. The estimate of the hazard ratio and corresponding 95%  CI will be 
provided using a Cox proportional hazards (CPH) model including treatment and the 
Protocol No.: 104 -13-302    Page 64 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 stratification factor s (maximum lesion diameter  [3-5 cm versus >5 –7 cm ] and RFA route 
[laparoscopic, open surgical, percutaneous] ) in the model. The survival curves will be 
estimated using Kaplan -Meier estimates. The stratification factor s will be populated as per 
the randomization assignment.  
15.3.2.2  OS - Supportive Analyses  
Supportive analyses for OS, conducted in the ITT population (unless otherwise noted), will 
include:  
a. The unstratified log -rank test and a CPH model (only treatment effect t in the model).  
b. Multivariate analysis using the CPH model, including the stratification factor s and the 
following set of potential prognostic/predictive factors: age (<  65 v. ≥  65), race 
(Caucasian, Asian, Other), region (EU and US, China, Korea, Other), baseline 
platelets, RFA start time, RFA dwell time (≤  45 min – for any outliers, ≥  45 min and 
≤ 90 min, ≥  90 min), device, disease etiology (Hep B, Other).   
Factors included in the model will be assessed for co -linearity and a stepwise 
selection process will be applied to identify a final subset of prognostic/predictive 
factors in the model. Once the subset has been established, treatment will be added to 
the final model to assess its effect.   
An exploratory analysis of treatment by factor interactions using the CPH model will 
be conducted, using the factors identified in the final model above.  
c. Subgroup analyses will also be conducted for the stratification factor s and the 
potential prognostic/predictive factors identified in Section 15.3.2.2 .b above. The HR 
and associated 95% CI will be presented for each subgroup.  
d. The primary efficacy analysis, as outlined in Section 15.3.2.1 , will also be run 
excluding any subjects that did not meet key eligibility criteria: a) single HCC lesion 
between ≥  3.0 and ≤  7.0 cm, b) ECOG performance status, c) RFA start time within 
20 minutes of starting the infusion, d) RFA dwell time ≥  45 minutes, and e) baseline 
platelets ≥ 75,000/mm3 and f ) Child -Pugh A classification . Additional sensitivity 
analyses will be defined in the SAP.  
 
15.3.2.3  Secondary Endpoint Analys es 
All secondary endpoints comparisons will be made at the 2 -sided 0.05 significance level. 
Since PFS is the only secondary endpoint for regulatory registration purposes, no further 
multiplicity adjustments will be made. Assuming that OS demonstrates significance at the 1 -
sided 0.025 level, PFS can subsequently be tested at the 1 -sided 0.025 level.    
 
PFS will be analyzed with methodology applied to the OS endpoint. Specifically, PFS will be 
analyzed with the methodology specified in Section 15.3.2.1  and 15.3.2.2 . Additional 
sensitivity analyses, as detailed in the SAP, will account for clinical progression as a PFS 
event.   
 
Protocol No.: 104 -13-302    Page 65 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 15.3.2.4  Safety Analyses  
The safety evaluations will focus primarily on AEs and laboratory assessments, but will also 
include physical examinations, vital signs, ECGs, echocardiograms/MUGA  scans 
hematology, clinical chemistry, and urinalysis beginning at time of signing of informed 
consent and continuing through Day 28 following study drug administration. . AEs after day 
28 visit which are assessed as possibly, probably or definitely related to study treatment will 
be recorded at any point during the trial. All subjects included in the As -Treated Population 
will be evaluated by treatment arm in the safety analysis.  
 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA) terminology and the severity of the toxicities will be graded according to the NCI 
CTCAE criteria, v4.03, where applicable.  Concomitant medications will be coded according 
to the World Health Organization (WHO) Medication Dictionary for Concomitant 
Medication.  
 
All AEs will be summarized (incidence) and listed by the System Organ Class (SOC), 
preferred term, toxicity/severity grade, and causal relationship to study medication. In 
addition, separate summaries of SAEs and Grade  3 and 4 AEs will be presented.  
 
Hematological and chemistry laboratory parameters will be graded according to the NCI 
CTCAE v.4.03 criteria, where applicable. Absolute values and changes from baseline will be 
summarized. In addition, worst severity grade, time to event, and time to resolution will also 
be summarized.  
 
15.4 Determination of Sample Size  
15.4.1  Study Population  
The study is designed to detect with 80% power a hazard ratio for OS of 0.67 (33% risk 
reduction) in the ThermoDox (TR) arm compared with the control (PR) arm with an overall 
1-sided type  1 error of  0.025. An OS hazard ratio of 0.63 was observed  among HEAT Study 
patients with a solitary 3 -7 cm lesion treated with ≥ 45 minutes of RFA. A 3%/year loss to 
survival follow -up rate has been assumed and using a 1:1 treatment allocation (TR:PR) of 
550 subj ects, a target of 197  events (deaths) will be required for the primary analysis.  
 
Based on these design operating characteristics and assuming a median survival time of 
approximately 4.5  years in the control arm, the primary analysis target events milestone  will 
be reached approximately 30  months after the last subject is randomized in the study. The 
median OS in the control arm was estimated based on the interim OS results in the HEAT 
study.   
 
15.5 Interim Analyses  
An independent Data Monitoring Committee (DMC) will periodically assess the safety data. 
A description of the roles and responsibilities and details of the review processes are 
provided in a separate DMC charter.  
Protocol No.: 104 -13-302    Page 66 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
  
Two interim analyses, both for efficacy and futility, are planned for the study. The first is 
planned after 60% of the target events is reached (118 deaths) and the second after 80% of 
the events has been reached (158 deaths). The Lan -DeMets alpha -spending approach will be 
used with O'Brien -Fleming stopping boundaries to evaluate efficacy. Fixed HR boundaries 
will be used to assess futility. This approach will account for multiple testing and preserve 
the overall 1 -sided study significance level of 0.025. Additional details will be provided in 
the DMC charter.  
 
No futility analyses are planned during the accrual period. Considering the relative short time 
of the accrual period compared to the slower accumulation rate of the events, there will not 
be sufficient events to make such assessment in the accrual study stage.  
 
 
16. DATA HANDLING  
16.1 Direct Access to Source Data/Documents  
The Investigator and institution agree that Celsion, its representatives (includes CRO, 
auditors , and monitors), the IRB/REB/IEC, and representatives from worldwide Regulatory 
Agencies will have the right, both during and after the clinical trial , to review and inspect 
pertinent medical records related to the clinical trial.  
 
The Investigator must maintain the primary records (i.e., source documents) of each subject’s 
data at all times. Examples of source documents are subject progress notes, clinic notes, 
hospital records, laboratory reports, drug inventory, study drug label records, and those CRFs 
that are used as source documentation.  
 
The Investigator will maintain a confidential subject identification list that allows the 
unambiguous identification of each subject. All study -related documents must be kept until 
notification by Celsion instructs otherwise.  
 
16.2 Quality Control and Quality Assurance  
16.2.1  Monitoring of the Study and Regulatory Compliance  
The project manager, or their monitor designee, will make an initiation site visit to each 
institution to review the protocol and its requirements with the Investigator(s), inspect the 
drug storage area, and fully inform the Investigator of his/her responsibilities and the 
procedures for assuring adequate and correct documentation. During the initiation site visit 
the case report forms (CRFs) and other pertinent study materials will be reviewed with the 
Investigator’s research staff. During the course of the study, the monitor will make regular 
site visits in order to review protocol compliance, examine CRFs and individual subjects’ 
medical records , and assure that the study is being conducted according to pertinent 
regulatory requirements. All CRF entries will be 100% verified with source documentation. 
The review of medical records will be done in a manner to assure that subject confidentiality 
Protocol No.: 104 -13-302    Page 67 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 is maintained. Sponsor or Regulatory body inspections may occur as well to assure the 
accuracy of study conduct.  
 
16.2.2  Curricula Vitae and Financial Disclosure of Investigators  
All Principal Investigators will be required to provide a current signed and dated curriculum 
vitae, a completed FDA Form 1572 , and a financial disclosure statement to Celsion or their 
authorized representative. In addition, all Sub-Investigators will be required to provide a 
current curriculum vitae and a financial disclosure statement.  
  
16.2.3  Protocol Modifications  
No modification of the protocol should be implemented without the prior written approval of 
the Sponsor or the Sponsor’s representative. Any such changes, which may affect a subject’s 
treatment or informed consent, especially those increasing potential risks, must receive prior 
approval by the IRB/REB/IEC. The exception to this is where modifications are necessary to 
eliminate an immediate hazard to trial subjects, or when the change involves only logistical 
or administrative aspects of the trial (e.g., change in monitor, change in telephone number).  
Other administrative revisions, which may affect the clinical portion of a study, will be duly 
reported to the IRB/REB/IEC by the Principal Investigator.  
 
16.3 Data Handling and Record Keeping  
The trial developed Case Report Form (CRF) is the primary data collection instrument for the 
trial. All subject data requested on the CRF must be supported by an d be consistent with the 
patient ’s source documentation. All missing data must be explained. When a laboratory test, 
assessment, or evaluation has not been performed or is “unknown”, a note should be created 
verifying that the field was “Not Done” or “Unknown”. For any entry error made, the errors 
must be corrected, and a note explaining the reason for change should be provided.    
 
Any electronic Case Report Forms (eCRF) system would be developed, maintained and 
utilized consistent with 21 CFR part 11 requirements. Authorized site personnel would 
require proper training on the system and would have an individual username and password 
to complete data entry and to address data clarifications . 
 
Any paper Case Report Forms will consist of two -part no -carbon -required paper (NCR) and 
should be completed in black ink (hard point pen). Incorrect data should not be obliterated. 
Use of white -out is prohibited. Any correction or deletion should be made by drawing a 
single line through the entry so that the original entry is still legible. This change must be 
initialed and dated by the site study coordinator or Investigator. The top sheet will be 
collected by the monitor. The bottom sheet is for the Investigator files and must be made 
available for review by Sponsor, IRB/REB/IEC, or appropriate regulatory agencies.  
 
Any changes made to data after collection will be made through the use of Data Clarification 
Forms (DCF). Data reported on the case report forms, which is derived from source 
documents , should be consistent with the source documents or the discrepancies should be 
explained. Case report forms will be considered complete when all missing and/or incorrect 
Protocol No.: 104 -13-302    Page 68 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 data have been resolved.  Please refer to the separate  Case Report Form Completion 
Guideline for further instructions.  
 
16.3.1  Data Collection  
Intraoperative data for device type, the number of ablation cycles , the RFA dwell time , probe 
type, tip length, and probe length will be documented.  
 
Note: A standard sRFA treatment is defined as the dwell time of ≥ 45 minutes measured from 
the first activation of the RFA probe to ablate tissue through turning off the RFA generator 
after the final ablation cycle. This includes the multiple ablation cycles and repositioning 
time between cycles for an individual patient.  
 
16.3.2  Recording of Data  
The Investigator will be responsible for the recording of all data on the CRFs provided, as 
certified by the Investigator’s signature and date on the designated pages. Should any value 
be significantly different from normal, the Investigator or designee will comment in the 
appropriate sections provided in the  CRFs.  
 
The Investigator will provide access to his/her original records to permit a representative 
from the Sponsor to verify the proper transcription of data. To facilitate photocopying, any 
paper CRF entries must be recorded legibly in black ink only. Erroneous entries will be 
crossed out with a single line, so as to remain legible. The correct value will be entered above 
the error and then initialed and dated by the person authorized to make the correction.  
 
16.3.3  Study Records  
Investigators in the United States, Canada or EU must maintain all study records for the 
indication under investigation for two years following the date a Product Licensing 
Application is approved or, if no application is to be filed or if the application is not approved 
for such indication, until two years after the investigation is discontinued and the FDA is 
notified.   
 
Investigators in Asia must maintain all study records for the indication under investigation 
for five years following the date a Product Licensing Application is approved.    
 
Subject’s  medical files should be retained in accordance with applicable legislation and in 
accordance with the maximum period of time permitted by the hospital, institution or private 
practice. Investigator must contact the Sponsor before moving or removing the study files.  
 
16.4 Financing and Insurance  
Financing and insurance information is provided for this study under separate cover . 
 
Protocol No.: 104 -13-302    Page 69 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 16.5 Publication Policy  
Since the Phase III study is a blinded, randomized , international study for registration 
purposes, no  individual  Investigator may publish or disclose clinical trial results until the 
study is completed. Study completion is defined as FDA review and response of the NDA 
submission. In addition, Institution acknowledges that, due to the limited patient population 
in its treatment group, the data generated from its individual participation in the Study and 
evaluation of its individual results may not be sufficient from which to draw any meaningful 
scientific conclusions.  
 
Upon study completion, Institution may, upon written notice to Sponsor , participate in a 
joint, multi -center publication of the study results with other third party P rincipal 
Investigators and/or institutions, provided that the proposed p ublication is first reviewed, 
commented , and approved by expressed written consent by Sponsor.  
 
Sponsor will provide authorship rights (and lead authorship rights) to Phase III site 
Investigators in order of greatest contribution of evaluable patients to the Phase III 
registration study. The term “evaluable” is distinguished from “enrollment contribution” and 
defined as patients that the FDA accepts as patients qualified for NDA approval. In addition, 
Sponsor may form a publication committee to evaluate and give final approval of publication 
submission.  
 
At least sixty (60) days prior to submitting a manuscript to a publisher or other outside 
persons (i.e., reviewer [s] or prior to any public presentation), a copy of the manuscript or 
presentation will be provided to Sponsor by the Investigator for review and comment. The 
Investigator understands and agrees that participation in the Study may involve a 
commitment to publish the results of the Study in a cooperative publication with other 
Investigators prior to publication or oral presentation on an individual basis. No publication 
of confidential information shall be made without Sponsor’s prior written consent, which 
shall not be unreasonably withheld or delayed. The Investigator agrees, following a request 
from Sponsor, to delete any confidential information which would prejudice the securing of 
adequate intellectual property protection from the proposed publication.  
 
 
17. ETHICAL CONSIDERATIONS  
The study will be conducted in the US under Investigational New Drug (IND) 
Application  66,827, in compliance with Title  21 of the Code of Federal Regulations (CFR), 
Part 50 (Protection of Human Subjects), and Part  56 (Institutional Review Board) as well as 
the principles of the Declaration of Helsinki and its amendments and local country -specific 
requirements. Institutional Review Boards (IRBs) reviewed and approved the protocol and 
informed consent. All subjects will be required to give written informed consent prior to 
participation in the study. This study will be performed in accordance with Good Clinical 
Practices (GCP) by qualified Investigators.  
 
The study specifically incorporates the following features:  
Protocol No.: 104 -13-302    Page 70 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 • Randomized study design  
• Blinding of subjects and Investigators  
• Parallel active control group  
• Prospectively stated objectives and analytical plan  
• Accepted, pre -specified outcome measures for safety and efficacy  
• Investigator meeting (an d/or a site initiation visit) prior to study start and a 
detailed protocol to promote consistency across sites  
• Compliance with Good Clinical Practices (GCP), with assessment via regular 
monitoring.  
 
Quality assurance procedures will be performed at study sites and during data management to 
assure that safety and efficacy data were adequate and well documented.  
 
17.1 Informed Consent  
The Investigator will obtain written informed consent from each subject (or their authorized 
representative) participating in the study. The form must be signed, witnessed and dated  
according to local acceptable standards .  The informed consent form will contain all the 
Essential Elements of Informed Consent set forth in 21  CFR Part 50, and the ICH Guideline 
for Good Clinical Practice, Section 4.8 (see Appendix VIII), and the terms of the Declaration 
of Helsinki. Copies of the signed document should be given to the subject and filed in the 
Investigator’s study file, as well as the subject’s medical record if in conformance with the 
institution’s Standard Operating Procedures.  
 
17.2 Institutional Review Board/Research Ethics Board/Independent 
Ethics Committee  
The study will not be initiated without approval of the appropriate Institutional Review 
Board/Research Ethics Board/Independent Ethics Committee (IRB/REB/IEC) and  will 
comply  with all administrative requirements of the governing body of the institution. This 
protocol, consent procedures, and any amendments must be approved by the IRB/REB/IEC 
in compliance with current regulations of the FDA and in accordance with ICH/GCPs. A 
letter of approval will be sent to the Sponsor prior to initiation of the study and when any 
subsequent modifications are made. The Sponsor or their authorized representative will keep 
the IRB/REB/IEC informed, as required by regulations, of the progress of the study as well 
as of any serious and unexpected adverse events.  
 
17.3 Subject Protection  
17.3.1  Subject Privacy  
In order to maintain patient confidentiality, all case report forms, study reports and 
communications relating to the study will identify subjects by initials and assigned subject 
numbers; subjects should not be identified by name. In accordance with local, national or 
federal regulations, the Investigator will allow the Sponsor or their designee personnel access 
Protocol No.: 104 -13-302    Page 71 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 to all pertinent medical records in order to verify the data gathered on the case report forms 
and to audit the data collection process. Regulatory agencies such as the US Food and Drug 
Administration (FDA) may also request access to all study records, including source  
documentation for inspection. No material bearing a patient’s name will be kept on file by 
the Sponsor and patients will be informed of their rights within the ICF.  
17.3.2  Rationale for Subject Selection  
The selection of subjects for this protocol will not be based on sex, race, or ethnic 
background.  
 
17.3.3  Participation of Children  
Children will not be enrolled in this study.  
 
 
18. TRIAL ADMINISTRATIVE INFORMATION  
18.1 Protocol Amendments  
As the trial progresses, any amendments to the study protocol deemed necessary will be 
communicated to the Investigator by Celsion or its designee. All protocol amendments will 
undergo the same review and approval process as the original protocol. A protocol 
amendment may be implemented after it has been approved by the IRB/REB/IEC, unless 
immediate implementation of the change is necessary for subject safety. In th at case, the 
situation must be documented and reported to the IRB/REB/IEC within 5 working days.  
 
Protocol No.: 104 -13-302    Page 72 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 19. REFERENCES  
 
1. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy -efficacy, safety, 
and pharmacologic basis of an intermittent single high -dosage schedule. Cancer. 
1974;33(1):19 -27. 
2. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal 
ablation of colorectal cancer metastases to the liver: a prospective study. J Clin 
Oncol. 2005 (a);23(7):1358 -64.. 
3. Berber E, Rogers S, Siperstein A. Predictors of survival after laparoscopic 
radiofrequency thermal ablation of hepatocellular cancer: a prospective study. Surg 
Endosc. 2005 (b);19(5):710 -4. 
4. Berber, E., et al., “Laparoscopic radiofrequency ablation of hepatic tumors” (2004) 
Surgical Endoscopy 18: 390 – 396. 
5. Berber E, Siperstein AE. Perioperative outcome after laparoscopic radiofrequency 
ablation of liver tumors: an analysis of 521 cases. Surg Endosc. 2007;21(4):613 -8. 
6. Bruix J, Sherman M . AASLD practice g uideline.  Management of hepatocellular 
carcinoma: an update. Hepatology. 2011;53(3):1020 -2. 
7. Buscarini L, Rossi S, Fornari F, Di Stasi M, Buscarini E. Laparoscopic ablation of 
liver adenoma by radiofrequency electrocauthery. Gastrointest Endosc. 
1995;41(1):68 -70. 
8. Chen MH, Wei Y, Yan K, Gao W, Dai Y, Huo L, et al. Treatment of strategy to 
optimize radiofrequency ablation for liver malignancies. J Vasc Interv Radiol. 
2006;17(4):671 -83. 
9. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective 
randomized trial comparing percutaneous local ablative therapy and partial 
hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321 -8. 
10. Chen MH, Yang W, Yan K, Zou MW, Solbiati L, Liu JB, et al. Large liver tumors: 
protocol for radiofrequency ablation and its clinical application in 110 patients - 
mathematic model, overlapping mode, and electrode placement process. Radiology. 
2004;232(1):260 -71.  
11. Curley SA. Radiofrequency ablation of malignant liver tumors. Oncologist 2001; 
6:14-23. 
12. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer 
metastasis. Cancer Metastasis Rev. 2004;23(1 -2):165 -82. 
13. Dodd GD 3rd, Frank MS, Aribandi M, Chopra S, Chintapalli KN. Radiofrequency 
thermal ablation: computer analysis of the size of the thermal injury created by 
overlapping ablations. AJR Am J Roentgenol. 2001;177(4):777 -82. 
14. Dodd GD 3rd, Napier D, Schoolfield JD, Hubbard L. Percutaneous radiofrequency 
ablation of hepatic tumors: postablation syndrome. AJR Am J Roentgenol. 
2005;185(1):51 -7. 
Protocol No.: 104 -13-302    Page 73 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 15. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Review: 
pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J 
Cancer. 1998;34(1):33 -46. 
16. Gasselhuber A, Dreher MR, Negussie A, Wood BJ, Rattay F, Haemmerich D. 
Mathematical spatio -temporal model of drug delivery from low temperature sensitive 
liposomes during radiofrequency tumour ablation. Int J Hyperthermia. 
2010;26(5):499 -513. 
17. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. 
Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant 
liposomal doxorubicin therapy. AJR Am J Roentgenol. 2002;179(1):93 -101. 
18. Haemmerich D, Rossmann C. Radiofrequency ablation + ThermoDox computational 
modeling study. Final Report (2013). New Jersey: Celsion Corporation. Data on file.  
19. Johnson PJ, Alexopoulos A, Johnson RD, Williams R. Significance of serum 
bilirubin level in response of hepatocellular carcinoma to doxorubicin. J Hepatol. 
1986;3(2):149 -53. 
20. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ 3rd. Mortality and hospital 
utilization for hepatocellular carcinoma in the United States. Gastroenterology. 
2005;129(2):486 -93. 
21. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC.  Radiofrequency ablation improves 
prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. 
Gastroenterology . 2004; 127(6):1714 -23. 
22. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised  controlled trial comparing 
percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, an 
dpercutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. 
Gut. 2005;54(8):1151 -6. 
23. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design 
and endpoints of clinical trials in hepatocellular carcinoma . J Natl Cancer Inst . 
2008; 100(10):698-711. 
24. Parkin DM , Bray F , Ferlay J , Pisani P . Global cancer statistics, 2002. CA Cancer J 
Clin. 2005;55:74 -108. 
25. Pfizer , Inc. Doxorubicin Hydrochloride for Injection, USP Prescribing Information 
Revised Jan. 2014  
26. Rhim H, Goldberg N, Dodd GD 3rd, Solbiati L, Lim HK, Tonolini M, et al. Essential 
techniques for successful radio -frequency thermal ablation of malignant hepatic 
tumors. Radiographics . 2001; 21:S17-39. 
27. Rossi S, Di Stasi, Buscarini E, Cavanna L, Quaretti P, Squassante L, et al. 
Percutaneous RF interstitial thermal ablation in the treatment of small hepatocellular 
carcinoma . Cancer J Sci Am. 1995 ;1(1):73-81. 
28. Shiina S , Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al.  A randomized 
controlled trial of radiofrequency ablation with ethanol injection for small 
hepatocellular carcinoma . Gastroenterology.  2005 ;129(1):122-30. 
Protocol No.: 104 -13-302    Page 74 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 29. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation 
of hepatic neuroendocrine tumor metastases. Surgery . 1997; 122(6):1147 -54. 
30. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 
2006 update of recommendations for the use of white blood cell growth factors: an 
evidence -based clinical practice guideline. J Clin Oncol. 2006;24(19):3187 -205. 
31. Swenson CE. A study of radiofrequency ablation + ThermoDox  in the swine liver. 
Study CEL -1301 (2014). New Jersey: Celsion Corporation. Data on file.  
32. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous 
radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases . 
Cancer. 2005 ;103(6):1201 -9. 
33. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular 
carcinoma. J Clin Oncol. 2005;23:8093 -108. 
34. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical 
features and prognosis of patients with extrahepatic metastases from hepatocellular 
carcinoma . World J Gastroenterol. 2007; 13(3): 414 -20. 
35. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng K, Eugeni M, et al. Phase I study of 
heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic 
malignancies. J Vasc Interv Radiol. 2012;23(2):248 -55. 
36. Yang Y,  Nagano H, Ota H, Morimoto O, Nakamura M, Wada H,  et al. Patterns and 
clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma 
after curative resection . Surgery . 2007; 141(2):196 -202. 
 
 
 
  
Protocol No.: 104 -13-302    Page 75 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20. APPENDICES  
20.1 Appendix I:  Child -Pugh Classification of Hepatic Impairment  
 
 Encephalopathy*  Ascites  Bilirubin  
(mg/dL )  Albumin  
(g/dL )  INR 
Score       
1 
 Absent  Absent  < 2 > 3.5 < 1.3 
2 
 I / II Mild / moderate  2 - 3 2.8 - 3.5 1.3 - 1.5 
3 
 III / IV  Severe  > 3 < 2.8 > 1.5 
* Encephalopathy grades:  
Grade 0: normal consciousness personality, neurological exam and electroencephalogram  
Grade 1: restless, sleep disturbed, irritable/agitated, impaired handwriting, 5 cps waves  
Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves  
Grade 3: somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves  
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cps activity  
 
Interpretation:  
Child Class A: 5 to 6 points  
Child Class B: 7 to 9 points  
Child Class C: 10 to 15 points  
 
Source:  
Child CG, Turcotte JG. Surgery  and portal hypertension. In: The liver and portal 
hypertension. Edited by CG Child. Philadelphia: Saunders . 1964:50 -64. 
 
Pugh RNH, Murray -Lyon IM, Dawson JL, Pietroni  MC, Williams R. Transection of the 
esophagus in bleeding oesophageal varices. Br J Surg . 1973;60:648 -52. 
 
 
 
 
 
Protocol No.: 104 -13-302    Page 76 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.2 Appendix II:  New York Heart Association (NYHA) Functional 
Classification for Heart Failure  
 
A functional and therapeutic classification for prescription of physical activity for cardiac 
patients.  
Class I: patients with no limitation of activities; they suffer no symptoms from ordinary 
activities.  
Class II: patients with slight, mild limitation of activity; they are comfortable with rest or 
with mild exertion.  
Class III: patients with marked limitation of activity; they are comfortable only at rest.  
Class IV: patients who should be at complete rest, confined to bed or chair; any physical 
activity brings on discomfort and symptoms occur at rest.  
 
Protocol No.: 104 -13-302    Page 77 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.3 Appendix III: Prohibited Medications  
 
The active ingredient  compound of ThermoDox (Doxorubicin) is a substrate (major) of 
CYP2D6, 3A4. Inducers and inhibitors of CYP3A4 may alter the metabolism of ThermoDox. 
The following CYP3A4 inducers and inhibitors are prohibited from screening through after 
study treatment.  Additionally, medications that could change the pharmacokinetic profile of 
ThermoDox or modify gastric pH are prohibited. Future updates to the list will be provided 
to the site as new information becomes available.  
 
Protocol No.: 104 -13-302    Page 78 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 Drug Class  Agent  Wash -out1 
CYP3A4 Inducers  
Antibiotics  all rifamycin class agents (e.g., rifampicin, 
rifabutin, rifapentine)  14 days  
Anticonvulsants  phenytoin, carbamazepine, barbiturates (e.g., 
phenobarbital)  
Antiretrovirals  efavirenz, nevirapine  
Glucocorticoids (oral)  cortisone (> 50 mg), hydrocortisone (> 40 mg),  
prednisone (> 10 mg), methylprednisolone (>  8 
mg), dexamethasone (> 1.5 mg, except the oral 
premedication which is part of the protocol)2  
Other  St. John’s Wort, modafinil   
CYP3A4 Inhibitors  
Antibiotics  clarithromycin, erythromycin, troleandomycin  
7 days  Antifungals  itraconazole, ketoconazole, fluconazole (> 150 mg 
daily), voriconazole  
Antiretrovirals, Protease 
Inhibitors  delaviridine, nelfinavir, amprenavir, ritonavir, 
indinavir, saquinavir, lopinivir  
Calcium channel blockers  verapamil, diltiazem  
Antidepressants  nefazodone, fluvoxamine  
GI Agents  cimetidine, aprepitant  
Other  grapefruit, grapefruit juice  
amiodarone  6 months  
Miscellaneous  
Antacids3 Mylanta, Maalox, Tums, Rennies  1 hour before and 
after dosing  
Herbal or dietary 
supplements  Ginkgo biloba, kava, grape seed, valerian, ginseng, 
echinacea, evening primrose oil  14 days  
Intravenous fat emulsions4  1 day before and 
after dosing  
Lipid complexed drugs  Fentanyl,  1 day before and 
after dosing  
Liposomal drugs  Abelect ™, Ambisome ™, Nyotran ™ 1 day before and 
after dosing  
 
1. At the time of screening, if a subject is receiving any of the above listed medications/substances, the 
medication or substance must be discontinued (if clinically appropriate) for the period of time 
specified prior to administration of the first dose of study drug treatment and throughout the period 
discussed above in order for the subject to be eligible to participate in the study.  
2. Glucocorticoid daily doses (oral)  1.5 mg dexamethasone (or equivalent) are allowed.  
Glucocorticoid conversions are provided in parentheses.  
3. Antacids may have an impact on absorption of oral premedication dexamethasone due to a change 
in stomach pH.  
4. Intravenous fat emulsions, with the exception of Propofol, are prohibited.  
 
 
 
Protocol No.: 104 -13-302    Page 79 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.4 Appendix IV: RFA Treatment Procedur e 
 
Treating Physician Qualifications  
• Must have performed radiofrequency ablation therapy on hepatic tumors in at least 15 
patients.  
• Must have used RFA device that will be used in protocol to treat hepatic tumors in at 
least 5 patients.  
Ablation Equipment  
Only FDA -approved RFA equipment marketed by Covidien, Boston Scientific Corp., and 
Angiodynamics (RITA) will be used in the protocol; however, each doctor (Principal 
Investigator or sub -Investigator) performing RFA will be limited to the use of a single 
manufacturer’s device for all treatments for an individual patient.  
• Covidien RFA Equipment  
Monopolar RF ablation generator with automated ablation algorithm (using the 
current model, which may be replaced with more current models during the 
course of the study.)  
Cool -Tip RF ablation needles.  
Covidien generator Switch Box.  
Dispersive Electrodes.  
• Boston Scientific Corp. RFA Equipment  
Radiofrequency Generator (using the current model, which may be replaced with 
more current models during the course of the study.)  
LeVeen Needle Electrodes.  
Dispersive Electrodes.  
• Angiodynamics (RITA)  RFA Equipment  
Radiofrequency Generator (using the current model, which may be replaced with 
more current models during the course of the study).  
StarBurst Electrodes.  
Dispersive Electrodes.  
 
Ablation Strategy for Individual Tumors   
The following are the minimum requirements for ablating tumors of a given size. At least 
4 ablation cycles lasting a total of ≥ 45 minutes should be performed.  Since all tumors are 
not perfect spheres, the operator should use the maximum diameter to choose the 
appropriate ablation strategy. All tumors should be treated with the goal of ablating the 
tumor as well as a 360o 1.0 cm tumor free margin around each tumor. Updated 
operational manuals for each RFA device, detailing the specifics of electrode vs. tumor 
size, should be followed accordingly.  
 
Protocol No.: 104 -13-302    Page 80 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.5 Appendix V: Adverse Events (AEs) and Criteria for Determining 
Relationship of AE to Treatment  
 
Criteria for Determining Category of Relationship of Clinical Adverse Events to 
Treatment  
 
1  
Not related   
This category applies to those adverse events, which, after careful 
consideration, are clearly and incontrovertibly due to extraneous causes 
(disease, environment, etc.).  
2 Unlikely  
(must have 
two) In general, this category can be considered applicable to those adverse 
events, which, after careful medical consideration at the time they are 
evaluated, are judged to be unrelated to the test drug or/and procedure.  
An adverse event may be considered unlikely if or when:  
  1. 
 
2. 
 
3. 
4. It does not follow a reasonable temporal sequence from administration 
of the test drug or/and procedure.  
It could readily have been produced by the subject’s clinical state, 
environmental or toxic factors, or other modes of therapy administered 
to the subject.  
It does not follow a known pattern of response to the drug/procedure.  
It does not reappear or worsen when the drug/procedure is re -
administered.  
3 Possibly  
(must have 
two) This category applies to those adverse events for which, after careful 
medical consideration at the time they are evaluated, a connection with 
the test drug or/and procedure administration appears unlikely but 
cannot be ruled out with certainty.  An adverse event may be 
considered possibly related if or when:  
  1. 
 
2. 
 
3. It follows a reasonable temporal sequence from administration of the 
test drug/procedure.  
It could not readily have been produced by the subject’s clinical state, 
environmental or toxic factors, or other modes of therapy administered 
to the subject.  
It follows a known pattern of response to the test drug/procedure.  
 
4  
Probably  
(must have 
three)   
This category applies to those adverse events for which, after careful 
medical consideration at the time they are evaluated, are felt with a 
high degree of certainty to be related to the test drug or/and procedure.  
An adverse event may be considered probably related if or when:  
Protocol No.: 104 -13-302    Page 81 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
   1. 
 
2. 
 
 
3. 
 
 
4. It follows a reasonable temporal sequence from administration of the 
test drug/procedure.  
It could not be reasonably explained by the known characteristics of 
the subject’s clinical state, environmental or toxic factors or other 
modes of therapy administered to the subject.  
It disappears or decreases on cessation or reduction in dose.   
There are important exceptions when an adverse event does not 
disappear upon discontinuation of the drug, yet drug -relatedness     
clearly exists (e.g., bone marrow depression, fixed drug eruptions, 
tardive dyskinesia).  
It follows a known pattern of response to the test drug/procedure.  
5 Definitely  
(must have 
all) This category applies to those adverse events that the Investigator feels 
are incontrovertibly related to test drug or/and procedure.  An adverse 
event may be assigned an attribution of definitely related if or when:  
  1. 
 
2. 
 
 
3. 
 
 
 
4. It follows a reasonable temporal sequence from administration of the 
test drug/procedure.  
It could not be reasonably explained by the known characteristics of 
the subject’s clinical state, environmental or toxic factors or other 
modes of therapy administered to the subject.  
It disappears or decreases on cessation or reduction in dose with re -
exposure to drug.  (Note: This is not to be construed as requiring 
re-exposure of the subject; however, a category of definitely related 
can only be used when a recurrence is observed.)  
 
It follows a known pattern of response to the test drug/procedure.  
 
The Investigators are to record the Outcome to Date  using the following four categories:  
Outcome  
Code  Descriptor  Definition  
1 Recovered  The patient fully recovered from the adverse event with 
no residual effect observable.  
2 Adverse Event 
Still Present  The adverse event itself is still present and observable.  
3 Adverse Event 
Resolved  The adverse event resolved, but residual effect(s) are 
still present and observable.   
4 Death  Death  
5 Unknown  The outcome of the adverse event could not be 
determined.  
 
Protocol No.: 104 -13-302    Page 82 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.6 Appendix VI:  ECOG Performance Status  
 
Grade  Functional Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours  
3 Capable of only limited self -care. Confined to bed or chair more than 50% of 
waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair  
5 Dead  
 
ECOG = Eastern Cooperative Oncology Group, Robert Comis MD, Group Chair.  
 
Source:  Oken MM , Creech R, Tormey DC, et al.  Toxicity and response criteria of the 
Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649 -655. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol No.: 104 -13-302    Page 83 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 20.7 Appendix VII: Requirements of Written Informed Consent 
Document (21  CFR 50.20 and 50.25 and ICH GCP, Topic E6, 
Section 4.8 ) 
 
Basic Elements of Informed Consent:  
In seeking informed consent, the following information shall be provided to each subject:  
• A statement that the study involves research, an explanation of the purpose of the 
research and the expected duration of the subject’s participation, a description of the 
procedures to be followed, and identification of any procedures that are 
experimental.  
• A description of any reasonably foreseeable risks or discomforts to the subject.  
• A description of any benefits to the subject or to others that may reasonably be 
expected from the research.  
• A disclosure of appropriate alternative procedures or courses of treatment, if any, 
which might be advantageous to the subject.  
• A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained and that notes the possibility that the Food 
and Drug Administration or other regulatory agency may inspect the records.  
For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treatments are available if injury 
occurs and, if so, what they consist of, or where further information may be obtained.  
An explanation of whom to contact for answers to pertinent questions about the research and 
research subject’s rights, and whom to contact in the event of a research -related injury to the 
subject.  
A statement that participation is voluntary, that refusal to participate will involve no penalty 
or loss of benefits to which the subject is otherwise entitled, and that the subject may 
discontinue participation at any time without penalty or loss of benefits to which the subject 
is otherwise entitled.  
Additional Elements of Informed Consent:  
When appropriate, one or more of the following elements of information shall also be 
provided to the subject:  
• A statement that the particular treatment or procedure may involve risks to the 
subject (or to the embryo or fetus, if the subject is or may become pregnant), which 
are currently unforeseeable.  
• Anticipated circumstances under which the subject's participation may be terminated 
by the Investigator without regard to the subject’s consent.  
• Any additional costs to the subject that may result from participation in the research.  
Protocol No.: 104 -13-302    Page 84 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
 • The consequences of a subject's decision to withdraw from the research and 
procedures for orderly termination of participation by the subject.  
• A statement that significant new findings developed during the course of the research 
which may relate to the subject's willingness to continue participation will be 
provided to the subject.  
• The approximate number of subjects involved in the study.  
   
Protocol No.: 104 -13-302    Page 85 of 103 
Version 2.0 14 -March -2014 
 
Celsion Corporation   Confidential  
  
20.8   Appendix VIII : AASLD Diagnostic Criteria  
 
This section summarizes diagnostic procedures  from the American Association for the Study 
of Liver Diseases ’ 2010 update to its practice guidelines (Bruix and Sherman 2011).  
 
HCC can be diagnosed radiologically, without the need for biopsy if the typical imaging 
features are present. This requires a contrast -enhanced study (dynamic CT -scan or MR). In 
the arterial phase, HCC enhances more intensely than the surrounding liver. In the venous 
phase, the HCC enhances less than the surrounding liver.  
  
Thus, to properly document the existence of HCC, a 4 -phase study is required: unenhanced, 
arterial, venous and delayed phases.  
  
For lesions above 1 cm in diameter, either dynamic MRI or multidetector CT scanner should 
be used.   If the appearances are typical for HCC on either MRI or CT scan, as described 
above, then no further investigation is required and the diagnosis of HCC is confirmed.   If the 
appearances are not typical for HCC (and do not suggest hemangioma), then one of two 
strategies is possible. A second study (the other of CT scan or MRI) could be performed. If 
the appearances are typical, the diagnosis is confirmed. Alternatively, an atypical study could 
trigger a biopsy.  
Protocol No.: 104 -13-302   Page 86 of 103 
Version 2.0, 14 -March -2014  
Celsion Corporation   Confidential  
  
 
 
 
  

Protocol No.: 104 -13-302   Page 87 of 103 
Version 2.0, 14 -March -2014  
Celsion Corporation   Confidential  
  
20.9   Appendix IX: Link to the most recent version of NCI Common 
Toxicity Criteria for Adverse Events (CTCAE), Version 4  
 
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
 
Protocol No.: 104 -13-302    Page 88 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
  
20.10  Appendix X: Description of Amendment Changes  
Protocol Version 1.0 13 -January -2014 to Version 2.0, 14 -March -2014  
 
Sect Description/Rationale  Changed to  Changed From  
Cover  Protocol Version Date  Version 2.0, 1 4-Mar-2014  Version 1.0, 13-Jan-2014  
Cover  The EudraCT Number was issued 
for this trial  2014 -000934 -53 2008 -000963 -41 
Synopsis, Section (S) 
3.3  ThermoDox , 
S8.1, S15.3.2.2  FDA requested stratification by 
RFA route.   Randomization and analysis will be 
stratified by maximum lesion diameter (3 -
5 cm versus > 5 -7 cm) and RFA route 
(laparoscopic, open surgical, 
percutaneous).  Randomization and analysis will be 
stratified by maximum lesion diameter 
(3-5 cm versus > 5 -7 cm)  
Synopsis, 5.1 Standardized monitoring interval 
for PFS to ensure consistency 
across sites  Following study treatment, s ubjects will 
undergo CT or MRI imaging scans  at 
months 1, 5, 9, 13, 17, 21, and 25 (+/ - 2 
weeks), then at 6 -month intervals (+/ - 2 
weeks) until radiological progression is 
seen..  Following study treatment, s ubjects 
will undergo CT or MRI imaging 
scans consistent with local standard of 
care at each institution  at an interval 
not > 6 months from the prior scan 
until radiological progression is seen.  
Protocol No.: 104 -13-302    Page 89 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
Synopsis, 6.2.3  Inclusion criteria update to 
characterize RFA eligibility and 
removed term. In additional all 
investigators  that are RFA 
operators will complete  formal 
training with an accompanying 
RFA training manual developed by 
the Sponsor.  
Overall health of livers since this is 
repetitive to the Child -Pugh Score 
inclusion criteria.  • The position and accessibility of the 
target lesion allows for the safe 
administration of multiple ablation 
cycles or deployments to achieve a 
probe dwell time of > 45 minutes.  
• DELETED “O verall health of the liver  
 • Procedure is expected to require 
multiple burn cycles or deployments 
to achieve an RFA probe dwell time 
≥ 45 minutes.  
• Overall health of the liver.  
 
Synopsis :  Exclusion 
Criteria  Amended to be consistent with the 
clinical program development to 
date  
 Platelet count < 75,000/mm3 Platelet count < 60,000/mm3 
Synopsis ;  
5.1: 8.3 Added term “Only” for 
clarification  Only FDA approved RFA devices are 
permitted for this trial.  FDA approved RFA devices are 
permitted for this trial  
Protocol No.: 104 -13-302    Page 90 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
Synopsis  Updated this section of the 
synopsis to be consistent with 
section 8.4 A standardized Radi ofrequency Ablation 
sRFA treatment for this protocol is 
defined as the dwell time of  ≥ 45 minutes 
measured from the first activation of the 
RFA probe to produce coagulative 
necrosis of target tissue through removal 
of the RFA probe after the final ablation 
cycle or deployment.  This includes the 
multiple ablation cycles and repositioning 
time between cycles for an individual 
patient . An ablation cycle for this 
protocol is defined as the single activation 
of the probe or electrode in order to 
achieve a local coagulation necrosis in 
target tissue. The cycle may  be completed 
by achieving a tar get temperature in the 
tissue or a target impedance.  A standardized Radi ofrequency 
Ablation (s)RFA treatment is defined 
as the dwell time of ≥ 45 minutes 
measured from the first activation of 
the RFA probe to ablate tissue 
through turning off the RFA generator 
after the final ablation cycle. This 
includes the multiple ablation cycles 
and repositioning time between cycles 
for an individual patient . 
 
PROTOCOL  
SYNOPSIS Synopsis,  
S4.2.1 , S15.3.2.4  AE reporting requirement update to 
confirm events possibly, probably 
or definitely related to study 
treatment will be recorded at any 
point during the trial  
 AEs which are assessed as possibly, 
probably, or definitely related to study 
treatment will be recorded at any point 
during the trial and must be  followed until 
resolution or until the patient is clinically 
stable . AEs which are assessed as possibly, 
probably, or definitely related to study 
treatment will be followed until 
resolution or until the patient is 
clinically stable . 
Protocol No.: 104 -13-302    Page 91 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
3.2 Clarification to note RFA for lesion 
>5 cm and < 7 cm may be outside 
standard treatment in some regions. 
The sRFA/ThermoDox 
combination is being investigated 
as a curative treatment rather than 
as a palliative treatment. Some 
centers may not enroll this 
population. The risks included in 
the consent form.  In the United States, palliative treatments 
such as transcatheter arterial 
chemoembolization (TACE) and sorafenib 
maybe standard treatment options  for HCC 
tumors > 5 cm. However, in this study the 
combination of RFA and ThermoDox is 
being investigated as a curative treatment 
for patients with tumors > 5 cm to < 7 cm 
rather than for their palliation.  
 
 
 New text.   
S4.2.1 , S12.4.1  PFS definitions clarified for 
consistency  PFS will be measured from the date of 
randomization to the first date on which 
one of the following occurs:  
 
• Death of any cause  
• Treatment failure (inability to 
achieve CR after two RFA ± 
ThermoDox treatment sessions)  
• Progression due to local tumor 
recurrence after initial CR  
• Progression due to distant 
intrahepatic tumor recurrence  
• Progression due to extrahepatic 
tumor recurrence  
 
 PFS will be measured from the date of 
randomization to the first date on 
which one of the following occurs:  
As determined by CT or MRI Scan  
An incomplete ablation following two 
RFA procedures  
Local recurrence of HCC tumor after 
complete initial ablation  
Any new distant intrahepatic HCC 
tumor  
Any new extrahepatic tumor  
Death from any cause  
 
Protocol No.: 104 -13-302    Page 92 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S6.2.4  Added text for explaining potential 
risks.  Doxorubicin HCl, the active agent in 
ThermoDox, is routinely given in 
chemotherapy regimens for multiple 
cycles after appropriate recovery intervals, 
usually at least 3 weeks. In contrast, the 
vast majority (84.8%; 291/343) of subjects 
in the RFA plus ThermoDox arm in the 
prior trial received only a single dose of 
ThermoDox.  
 Doxorubicin HCl, the active agent in 
ThermoDox, is routinely given in 
chemotherapy regimens for multiple 
cycles after appropriate recovery 
intervals, usually at least 3 weeks.  
S6.2.4  Added text for explaining potential 
risks for patients with elevated 
bilirubin levels at baseline and to 
describe plan to mitigating risk 
during the trial  In the prior study, subjects with baseline 
serum bilirubin > 2.0 mg/dL had a higher 
incidence subsequent grade 3+ 
hyperbilirubinemia and of grade 3+ 
hepatic failure. However, the greater 
incidence of hepatic failure consisted of a 
single patient with grade 3 liver failure. 
Among patients with an elevated bilirubin 
level at baseline, there were no subsequent 
serious hepatobiliary adverse events 
except for 2 cases of 
hyperbilirubinemia/blood bilirubin 
increased. The DMC is responsible for 
unblinded monitoring of subjects with 
elevated (> 2.0 mg/dL and < 3.0 mg/dL) 
serum bilirubin levels and will advise if 
any dose or protocol modification is 
needed to mitigate risk to such patients.  New text.  
Protocol No.: 104 -13-302    Page 93 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S6.2.4  Include potential for increased risk 
to patients if a biopsy has not 
confirmed HCC.  AASLD treatment guidelines permit the 
diagnosis with the use of imaging 
modality only without a biopsy 
histological or cytological confirmation of 
the specimen. Procurement of a biopsy 
increases risk to subjects with liver disease 
and therefore is not always indicated. 
However patients who undergo an RFA 
treatment without a biopsy may be at 
increased risk for undergoing an 
unnecessary ablation or be at risk for 
seeding for subcapsular or poorly 
differentiated disease. This risk is minimal 
and accepted within clinical practice 
guidelines.  
 New Text  
Protocol No.: 104 -13-302    Page 94 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S6.2.4  Include potential increased risk for 
subjects whose lesions are > 5 cm.  RFA has been used safely in tumors up to 
7 cm (Chen, et al. 2004; Curley, et al. 
2004; Dodd, et al. 2001; Tateishi, et al. 
2005).  In the United States and other local 
regions, palliative treatments such as 
transcatheter arterial chemoembolization 
(TACE) and sorafenib are the standard of 
care for HCC tumors > 5 cm. However, in 
this study the combination of RFA and 
ThermoDox is being investigated as a 
curative treatment for patients with tumors 
> 5 cm to < 7 cm rather than for their 
palliation. There is risk that RFA is not as 
effective in the larg er tumors, however this 
has not been established. Subjects would 
be eligible to receive palliative therapy as 
medically indicated after progression is 
observed  New Text  
S 7.2 Study Discontinuation - New text to 
clarify subjects may select to 
continue in OS. Site personnel 
should discusswith subject.  If a subject discontinues from retreatments 
or from the PFS imaging interval, the 
patient should still be contacted for overall 
survival until withdraw consent for study 
participation.  New text  
Protocol No.: 104 -13-302    Page 95 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S7.3 Study non -compliance - New text to 
clarify subjects may continue in 
OS. Site personnel should discuss 
with subject.  If a subject is discontinued from the study 
due to noncompliance of follow up visits, 
the patient should still be contacted for 
overall survival until end of study or 
withdraw consent f rom study participation.  
 New text  
S8.5.4  Guidance to investigator for non -
hematologic toxicities >grade 3 
prior to a retreatment  Among patients requiring re -treatment 
after incomplete initial ablation who have 
developed a non -hematologic toxicity ≥ 
grade 3, no dose modification is required. 
Instead, such subjects will not be re -
treated until the severity of the non -
hematologic toxicity drops to < grade 2.  
 New text.   
S10.1.4 , 
S10.1.5 , S10.1.8  Standardized 4 month safety 
interval surveillance to include PE, 
Vitals, ECGs.  • Month 5, Month 9, Month 13 (+/ - 2 
weeks) or disease progression, 
whichever occurs first  
 
 Patients who receive study 
retreatment will have an additional 
physical exam at Month 3 following 
each retreatment.  
 
Protocol No.: 104 -13-302    Page 96 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S10.1.7  Standardized 4 month PFS 
secondary endpoint monitoring  CT or MRI scans (Chest, Abdomen, and 
Pelvis) will be done within 21 days prior 
to study treatment to confirm the presence 
of an evaluable lesion and at Day 28 to 
assess whether a complete initial ablation 
was achieved. Additional imaging will be 
done at months, 5, 9, 13, 17, 21, 25, then 
every 6 months (+/ - 2 weeks) until disease 
progression is seen. The following 
requirements apply to imaging for this 
study:  
• The same modality and technique 
must be used for all scans of an 
individual patient.  
 CT or MRI scans will be done within 
21 days prior to study treatment to 
confirm the presence of an evaluable 
lesion and at Day 28 to assess whether 
a complete initial ablation was 
achieved. Imaging procedures, follow -
up intervals, and the determination of 
progression will be done according to 
the local standard of care with the 
following exceptions:  
• The same modality and 
technique must be used for all 
scans of an individual patient.  
• The follow up imaging 
interval cannot exceed 6 
months.  
 
S10.1.9  1 month adjustment for LVEF 
exam at 1 year and then language 
to advise when repeat scan is 
necessary.  Follow -up scans must be completed on 
Day 28 (+/ - 3 days) and at Month 13 or at 
time progression of disease, whichever 
occurs first.  
A decrease of >10% in resting LVEF that 
becomes abnormal (lower than the 
institutional lower limit of normal) should 
be further evaluated by repeat examination 
for subjects with a total cumulative 
doxorubicin of ≥  300 mg/m2.  
 Follow -up scans must be completed on 
Day 28 (+/ - 3 days) and at Month 12 
or at time progression of disease, 
whichever occurs first.   
Protocol No.: 104 -13-302    Page 97 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S10.1.11  Standardized long term safety 
surveillance for Liver Function 
Testing  Additional post -treatment liver function 
tests (Chemistry and PT/I NR), will be 
collected at months 5, 9, 13, 17, 21 and 25  
(+/- 2 weeks) or disease progression, 
whichever occurs first.  Post-treatment liver function tests 
(Chemistry and PT/INR), will be 
collected at intervals not to exceed 6 
months following study drug 
administration through Month 12.  
S10.2 Clarification to simplify 
understanding.  The second ablation must occur no later 
than 21 days after the first post -ablation 
scan assessment at Day 28.  The second ablation must occur  no 
earlier than 21 days after the initial 
ablation and no later than 21 days after 
the first post -ablation scan assessment 
at Day 28.  
 
S10.3 Imaging intervals and liver 
function test intervals are 
standardized elsewhere in the 
protocol  No replacement language  Radiological Imaging interval and 
Liver Function Test can be scheduled 
according to local standard treatment 
guidelines at intervals not to exceed 6 
months. The radiological imaging will 
continue until Investigator determined 
radiological progression. The Liver 
Function Tests are to be monitored 
through Month 12 following last study 
drug infusion.  
 
Protocol No.: 104 -13-302    Page 98 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S12.1 Assessment of efficacy definitions 
were added to the protocol to 
ensure consistency across sites  All patients will be monitored for survival 
by recording their visits during routine 
follow up for response to treatment.  The 
visits are scheduled to occur every four 
months from the first imaging study 
confirming complete ablation until month 
25 or radiological progression, whichever 
comes first.   If patients have not 
demonstrated radiological progression at 
month 25 then the imaging visit schedule 
is reduced to every six months until 
progression.   Survival is confirmed at 
every imaging visit.  
Once radiological progression is 
confirmed then follow up for survival is 
required.  Sites are required to confirm 
contact with the subject during either a 
clinic visit or a telephone contact every 
three months.  It is expected that subject 
follow up will be about five years.  
 Additional language.   
Protocol No.: 104 -13-302    Page 99 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S12.2 Secondary Endpoint progression 
free survival includes mRESIST 
details to ensure consistency during 
standardized interval training.  The protocol incorporates modified 
RECIST (mRECIST) developed for HCC 
clinical research as a basis to evaluate 
tumor response.  The mRECIST enables 
assessment of overall response by taking 
into account target lesion response, and 
presence or absence of new lesions.  A 
separate imaging manual and imaging 
training program has been developed for 
this study in order to ensure uniformity in 
imaging technique and imaging review in 
accordance with mRECIST.  
 Additional language.  
Protocol No.: 104 -13-302    Page 100 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S12.3 Baseline Assessment definitions 
added for consistency  The baseline assessment must include a 
comprehensive evaluation of the chest, 
abdomen and pelvis.  The HCC tumor 
identified on the eligibility scan should be 
defined as target lesion and its longest 
diameter should be measured on the 
contrast -enhanced CT or contrast -
enhanced MRI scan. This measurement 
should reflect the overall longest tumor 
diameter, regardless of the presence of 
internal areas of spontaneous necrosis. In 
the study protocol, intermediate size is 
defined as a tumor lesion larger than 3.0 
cm but not exceeding 7.0 cm in longest 
diameter. Since the study will recruit 
patients with solitary tumors and no 
evidence of vascular invasion or 
extrahepatic spread, the eligible size HCC 
lesion detected on the eligibility scan is 
expected to be the only target lesion. No 
additional target or non -target lesions 
should be detectable on the eligibility scan 
to allow enrollment in the study  
 Additional language.  
Protocol No.: 104 -13-302    Page 101 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S12.4 Target lesion local response and 
local recurrence added for guidance 
to investigators in reporting PFS 
endpoint.  The image acquisition protocols used for 
any post -baseline assessments should be 
consistent with the protocol used for the 
baseline eligibility scan. Baseline images 
for treatment eligibility will be confirmed 
centrally before RFA treatment.  
Investigator determined radiological 
confirmation of complete ablation will 
occur at one month post RFA.  If initial 
RFA is incomplete then a second, and 
final, attempt may be made for a complete 
ablation for subject to stay on protocol. 
Once a complete ablation is confirmed 
then patients are monitored radiol ogically 
until progression.  The imaging interval 
will be every four months until month 25 
then every six months thereafter.  No 
imaging studies are required once 
progression is confirmed.  
 
The disappearance of any intratumoral 
enhancement in the target tumor lesion 
after treatment with study treatment will 
be classified as complete response (CR), 
while the persistence of any areas of 
intratumoral enhancement consistent with 
residual viable tumor will be considered as 
incomplete response (IR). Failure to 
achieve a CR after two RFA ± 
ThermoDox treatment sessions will be 
classified as treatment failure. Tumor 
recurrence detected within or around the 
target lesion after having achieved initial 
CR will be classified as local recurrenc e. 
Tumor recurrences will be defined as local 
if they are located 1 cm or less from the 
ablation margin  
 Additional language.  
Protocol No.: 104 -13-302    Page 102 of 103 
Version 2.0, 14 -March -2014  
 
Celsion Corporation   Confidential  
 Sect Description/Rationale  Changed to  Changed From  
S12.4.1  New definition of Equivocal 
response  in newly created Table 
3 and addition of Table 2Table 4, 
Overall Responses for Possible 
combination of Tumor 
Responses.   Equivocal (EQ)  
A new liver lesion that is smaller than 1 
cm in longest diameter OR fails to show a 
typical enhancement profile should be 
considered as equivocal and not 
conclusive for disease progression. Such 
lesions can be diagnosed as HCC by 
evidence of either a change in 
enhancement pattern OR at least 1 -cm 
interval growth in subsequent scans.  
*Plus Table 4 titled Overall Responses for 
possible combination of tumor responses 
in the target lesion with or without the 
appearance of new intrahepatic or 
extrahepatic lesions.  
 New text.   
S14 Additional responsibilities for the 
DMC.   A Data Monitoring Committee (DMC) 
will evaluate safety data on an ongoing 
basis at regular intervals during subject 
accrual and follow -up. The DMC is 
responsible for unblinded monitoring of 
subjects with elevated (> 2.0 mg/dL and < 
3.0 mg/dL) serum bilirubin levels and will 
advise if any dose or protocol modification 
is needed to mitigate risk to such patients. 
The Sponsor is responsible to report 
relevant SAEs to applicable local, 
national, and/or international regulatory 
body.  A Data Monitoring Committee (DMC) 
will evaluate safety data on an ongoing 
basis at regular intervals during subject 
accrual and follow -up. The Sponsor is 
responsible to report relevant SAEs to 
applicable local, national, and/or 
international regulatory body.   
Protocol No.: 104 -13-302    Page 103 of 103 
Version 2.0, 14 -March -2014  
Celsion Corporation   Confidential  
  
END OF PROTOCOL  
 